<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="efs29470" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EFSA J</journal-id><journal-id journal-id-type="iso-abbrev">EFSA J</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1831-4732</journal-id><journal-id journal-id-type="publisher-id">EFS2</journal-id><journal-title-group><journal-title>EFSA Journal</journal-title></journal-title-group><issn pub-type="epub">1831-4732</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12099302</article-id><article-id pub-id-type="doi">10.2903/j.efsa.2025.9470</article-id><article-id pub-id-type="publisher-id">EFS29470</article-id><article-id pub-id-type="other">EFSA-2025-0262</article-id><article-categories><subj-group subj-group-type="JEL-classification"><subject>Nutr1010</subject></subj-group><subj-group subj-group-type="overline"><subject>Scientific Opinion</subject></subj-group><subj-group subj-group-type="heading"><subject>Scientific Opinion</subject></subj-group></article-categories><title-group><article-title>Phenolic compounds naturally present in olive oil and lowering of blood <styled-content style="fixed-case" toggle="no">LDL</styled-content>&#x02010;cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease: Evaluation of a health claim pursuant to Article 14 of Regulation (<styled-content style="fixed-case" toggle="no">EC</styled-content>) No 1924/2006</article-title><alt-title alt-title-type="right-running-head">Phenolic compounds naturally present in olive oil and lowering of blood <styled-content style="fixed-case" toggle="no">LDL</styled-content>&#x02010;c, <styled-content style="fixed-case" toggle="no">SBP</styled-content> and reduction of <styled-content style="fixed-case" toggle="no">CHD</styled-content> riskPhenolic compounds in olive oil and lowering of blood <styled-content style="fixed-case" toggle="no">LDL</styled-content>&#x02010;c, <styled-content style="fixed-case" toggle="no">SBP</styled-content> and reduction of <styled-content style="fixed-case" toggle="no">CHD</styled-content> risk</alt-title></title-group><contrib-group><contrib id="efs29470-cr-0001" contrib-type="author" corresp="yes"><collab collab-type="authors">EFSA Panel on Nutrition, Novel Foods and Food allergens (NDA)</collab><address><email>nif@efsa.europa.eu</email></address></contrib><contrib id="efs29470-cr-0002" contrib-type="author"><name><surname>Turck</surname><given-names>Dominique</given-names></name></contrib><contrib id="efs29470-cr-0003" contrib-type="author"><name><surname>Bohn</surname><given-names>Torsten</given-names></name></contrib><contrib id="efs29470-cr-0004" contrib-type="author"><name><surname>C&#x000e1;mara</surname><given-names>Monta&#x000f1;a</given-names></name></contrib><contrib id="efs29470-cr-0005" contrib-type="author"><name><surname>Castenmiller</surname><given-names>Jacqueline</given-names></name></contrib><contrib id="efs29470-cr-0006" contrib-type="author"><name><surname>de Henauw</surname><given-names>Stefaan</given-names></name></contrib><contrib id="efs29470-cr-0007" contrib-type="author"><name><surname>Hirsch&#x02010;Ernst</surname><given-names>Karen&#x02010;Ildico</given-names></name></contrib><contrib id="efs29470-cr-0008" contrib-type="author"><name><surname>Jos</surname><given-names>Angeles</given-names></name></contrib><contrib id="efs29470-cr-0009" contrib-type="author"><name><surname>Maciuk</surname><given-names>Alexandre</given-names></name></contrib><contrib id="efs29470-cr-0010" contrib-type="author"><name><surname>Mangelsdorf</surname><given-names>Inge</given-names></name></contrib><contrib id="efs29470-cr-0011" contrib-type="author"><name><surname>McNulty</surname><given-names>Breige</given-names></name></contrib><contrib id="efs29470-cr-0012" contrib-type="author"><name><surname>Naska</surname><given-names>Androniki</given-names></name></contrib><contrib id="efs29470-cr-0013" contrib-type="author"><name><surname>Pentieva</surname><given-names>Kristina</given-names></name></contrib><contrib id="efs29470-cr-0014" contrib-type="author"><name><surname>Thies</surname><given-names>Frank</given-names></name></contrib><contrib id="efs29470-cr-0015" contrib-type="author"><name><surname>Drenjan&#x0010d;evi&#x00107;</surname><given-names>Ines</given-names></name></contrib><contrib id="efs29470-cr-0016" contrib-type="author"><name><surname>Craciun</surname><given-names>Ionut</given-names></name></contrib><contrib id="efs29470-cr-0017" contrib-type="author"><name><surname>Fiolet</surname><given-names>Thibault</given-names></name></contrib><contrib id="efs29470-cr-0018" contrib-type="author"><name><surname>Siani</surname><given-names>Alfonso</given-names></name></contrib></contrib-group><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>&#x000a0;<email>nif@efsa.europa.eu</email>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>23</volume><issue seq="280">5</issue><issue-id pub-id-type="doi">10.1002/efs2.v23.5</issue-id><elocation-id>e9470</elocation-id><permissions><!--&#x000a9; European Food Safety Authority--><copyright-statement content-type="article-copyright">&#x000a9; 2025 European Food Safety Authority. <italic toggle="yes">EFSA Journal</italic> published by Wiley&#x02010;VCH GmbH on behalf of European Food Safety Authority.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyndlicense">https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">http://creativecommons.org/licenses/by-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:EFS2-23-e9470.pdf"/><abstract><title>Abstract</title><p>Following an application from QvExtra! Internacional pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Spain, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to phenolic compounds naturally present in olive oil and lowering of blood LDL&#x02010;cholesterol (LDL&#x02010;c) and systolic blood pressure (SBP), therefore reducing the risk of coronary heart disease (CHD). The scope of the application was proposed to fall under a health claim referring to disease risk reduction. The Panel considers that the food/constituent, phenolic compounds naturally present in olive oil, is sufficiently characterised, and that lowering of blood LDL&#x02010;c and SBP are beneficial effects by reducing the risk of CHD. The applicant identified seven pertinent human intervention studies investigating the effect of olive oil polyphenols on LDL&#x02010;c and/or SBP. In weighing the evidence with regard to blood LDL&#x02010;c, the Panel considered that, although one human intervention study in hypercholesteraemic individuals showed a reduction in LDL&#x02010;c following daily consumption of olive oil polyphenols for 3&#x02009;weeks, these results are not supported by other studies. The Panel also considered that no evidence was available for the sustainability of the effect over longer periods of time (e.g. &#x02265;&#x02009;8&#x02009;weeks), or for a plausible mechanism of action. In weighing the evidence with regard to SBP, the Panel took into account that, although some evidence for a plausible mechanism by which phenolic compounds in olive oil could exert the claimed effect has been provided, the studies submitted did not show an effect of olive oil polyphenols on SBP. The Panel concludes that a cause&#x02010;and&#x02010;effect relationship has not been established between the consumption of phenolic compounds naturally present in olive oil and the reduction of blood LDL&#x02010;c or SBP.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="efs29470-kwd-0001">coronary heart disease</kwd><kwd id="efs29470-kwd-0002">LDL&#x02010;c</kwd><kwd id="efs29470-kwd-0003">phenolic compounds</kwd><kwd id="efs29470-kwd-0004">polyphenols</kwd><kwd id="efs29470-kwd-0005">SBP</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="22"/><word-count count="14300"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="EFS29470-cit-2001">
<collab collab-type="authors">EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food allergens)</collab>
, <string-name>
<surname>Turck</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bohn</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>C&#x000e1;mara</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Castenmiller</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>de Henauw</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hirsch&#x02010;Ernst</surname>, <given-names>K.&#x02010;I.</given-names>
</string-name>, <string-name>
<surname>Jos</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Maciuk</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mangelsdorf</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>McNulty</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Naska</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pentieva</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Thies</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Drenjan&#x0010d;evi&#x00107;</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Craciun</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Fiolet</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Siani</surname>, <given-names>A.</given-names>
</string-name> (<year>2025</year>). <article-title>Phenolic compounds naturally present in olive oil and lowering of blood <styled-content style="fixed-case" toggle="no">LDL</styled-content>&#x02010;cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease: Evaluation of a health claim pursuant to Article 14 of Regulation (<styled-content style="fixed-case" toggle="no">EC</styled-content>) No 1924/2006</article-title>. <source>EFSA Journal</source>, <volume>23</volume>(<issue>5</issue>), <elocation-id>e9470</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2025.9470</pub-id>
</mixed-citation>
</p><fn-group id="efs29470-ntgp-0001"><fn id="efs29470-note-0001"><p>Adopted: 6 May 2025</p></fn><fn id="efs29470-note-0002"><p>The declarations of interest of all scientific experts active in EFSA's work are available at <ext-link xlink:href="https://open.efsa.europa.eu/experts" ext-link-type="uri">https://open.efsa.europa.eu/experts</ext-link>
</p></fn></fn-group></notes></front><body id="efs29470-body-0001"><sec id="efs29470-sec-0001"><label>1</label><title>INTRODUCTION</title><sec id="efs29470-sec-0002"><label>1.1</label><title>Background and Terms of Reference as provided by the requestor</title><p>Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14&#x02013;17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children's development and health in a Community list of permitted claims. According to this Regulation, an application shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).</p></sec><sec id="efs29470-sec-0003"><label>1.2</label><title>Interpretation of the Terms of Reference</title><p>EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to phenolic compounds in olive oil and lowering of blood LDL&#x02010;cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease.</p><p>The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of phenolic compounds in olive oil, a positive assessment of their safety or a decision on whether olive oil phenolic compounds are, or are not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.</p><p>It should also be highlighted that the scope, the proposed wording of the claim and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.</p></sec></sec><sec id="efs29470-sec-0004"><label>2</label><title>DATA AND METHODOLOGIES</title><sec id="efs29470-sec-0005"><label>2.1</label><title>Data</title><sec id="efs29470-sec-0007"><title>Information provided by the applicant</title><p>See also section Steps taken by EFSA at the end of this opinion.</p></sec><sec id="efs29470-sec-0008"><title>Food/constituent as stated by the applicant</title><p>According to the applicant, the constituent for which the health claim is made is &#x02018;phenolic compounds naturally present in virgin olive oil&#x02019;.</p></sec><sec id="efs29470-sec-0009"><title>Health relationship as claimed by the applicant</title><p>Upon a request from EFSA, the applicant clarified the claimed health effect is the lowering of blood LDL&#x02010;cholesterol and systolic blood pressure, risk factors for coronary heart disease.</p></sec><sec id="efs29470-sec-0010"><title>Mechanism by which the food/constituent could exert the claimed effect as proposed by the applicant</title><p>Regarding the mechanism by which phenolic compounds in olive oil could decrease blood LDL&#x02010;cholesterol, the applicant suggests that &#x02018;The decrease in LDL concentrations may be explained through an improvement in the systemic oxidative status or by an increase in the gene expression of lipoprotein lipase. An improved oxidative status due to the consumption of olive oil polyphenols may counteract increases in LDL concentrations by decreasing the number of small LDL particles.&#x02019; Additionally, the applicant suggests olive oil polyphenols &#x02018;enhance the expression of cholesterol efflux&#x02010;related genes&#x02019;.</p><p>Regarding the mechanism for blood pressure reduction, the applicant suggests that &#x02018;the polyphenols can stimulate the formation of vasoprotective factors, such as nitric oxide (NO) and endothelium&#x02010;derived hyperpolarising factor (EDHF) to promote vasodilatation, inhibit platelet aggregation in humans and they can also improve vascular smooth muscle function, by reducing the excessive vascular oxidative stress of pathological blood vessels associated with many cardiovascular risk factors.&#x02019; Additionally, the applicant proposes a reduction of blood pressure &#x02018;through modulating the expression of genes that are related to the renin&#x02013;angiotensin&#x02013;aldosterone system (RAAS)&#x02019;.</p></sec><sec id="efs29470-sec-0011"><title>Wording of the health claim as proposed by the applicant</title><p>The applicant has proposed the following wording for the health claim: &#x02018;Naturally present phenolic compounds in any virgin olive oil reduce the LDL&#x02010;cholesterol in blood and arterial systolic blood pressure. A reduction of LDL&#x02010;cholesterol in blood or arterial systolic blood pressure reduces coronary heart disease.&#x02019;</p></sec><sec id="efs29470-sec-0012"><title>Specific conditions of use as proposed by the applicant</title><p>According to the applicant, the target population for the claimed effect is &#x02018;general healthy and subgroup with mildly raised LDL&#x02010;c and blood pressure&#x02019;. The applicant recommends &#x02018;The oil should be consumed at least in a quantity of 35 mL, to have 8 mg of phenols; and 55 mL to have 12 mg (for a significant decrease in LDL&#x02010;C and SBP respectively). To do this we must consume at least 40 mL of virgin olive oil, which would be equivalent to 4 tablespoons daily&#x02019; to achieve the claimed effect.</p><p>The applicant also states that &#x02018;the natural phenols content in the virgin olive oil should be at least 200 mg/kg.&#x02019;</p></sec><sec id="efs29470-sec-0013"><title>Data provided by the applicant</title><p>The health claim application on phenolic compounds in olive oil pursuant to Article 14 of Regulation (EC) No 1924/2006 was presented in a common and structured format as outlined in the Scientific and technical guidance for the preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0009" ref-type="bibr">2021b</xref>).</p><p>As outlined in the General guidance for stakeholders on health claim applications (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0008" ref-type="bibr">2021a</xref>), it is the responsibility of the applicant to provide the totality of the available evidence.</p><p>The applicant has submitted a confidential and a non&#x02010;confidential version of a dossier following the &#x02018;General scientific guidance for stakeholders on health claim applications&#x02019; (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0008" ref-type="bibr">2021a</xref>) and the &#x02018;Scientific and technical guidance for the preparation and presentation of a health claim application&#x02019; (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0009" ref-type="bibr">2021b</xref>).</p><p>The application does not contain data claimed as confidential or proprietary by the applicant.</p><p>In accordance with Art. 38 of Regulation (EC) No 178/2002<xref rid="efs29470-note-1003" ref-type="fn">
<sup>1</sup>
</xref> and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality,<xref rid="efs29470-note-1004" ref-type="fn">
<sup>2</sup>
</xref> the non&#x02010;confidential version of the dossier has been published in the OpenEFSA portal.<xref rid="efs29470-note-1005" ref-type="fn">
<sup>3</sup>
</xref>
</p></sec></sec><sec id="efs29470-sec-0014"><label>2.2</label><title>Methodologies</title><p>The general approach of the NDA Panel for the evaluation of health claim applications is outlined in the EFSA General guidance for stakeholders on health claim applications (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0008" ref-type="bibr">2021a</xref>).</p><p>In assessing each specific food/health relationship, which forms the basis of a health claim, the NDA Panel considers the following key criteria:
<list list-type="roman-lower" id="efs29470-list-0001"><list-item id="efs29470-li-0001"><p>the food/constituent is defined and characterised;</p></list-item><list-item id="efs29470-li-0002"><p>the claimed effect is based on the essentiality of a nutrient; OR the claimed effect is defined and is a beneficial physiological effect for the target population and can be measured in&#x000a0;vivo in humans;</p></list-item><list-item id="efs29470-li-0003"><p>a cause and effect relationship is established between the consumption of the food/constituent and the claimed effect (for the target group under the proposed conditions of use).</p></list-item></list>
</p><p>Each of these three criteria needs to be assessed by the NDA Panel with a favourable outcome for a claim to be substantiated. In addition, an unfavourable outcome of the assessment of criterion (i) and/or (ii) precludes the scientific assessment of criterion (iii).</p><p>The scientific requirements for health claims related to cardiovascular health are outlined in a specific EFSA guidance (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0007" ref-type="bibr">2018</xref>).</p></sec><sec id="efs29470-sec-0015"><label>2.3</label><title>Public consultation</title><p>According to Art. 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre&#x02010;submission phase and public consultations, EFSA carried out a Public Consultation (PC) on the non&#x02010;confidential version of the application from 21 February 2025 to 14 March 2025 (<ext-link xlink:href="https://connect.efsa.europa.eu/RM/s/consultations/publicconsultation2/a0lTk000003mGjt/pc1329" ext-link-type="uri">PC&#x02010;1329</ext-link>) for which six comments were received. The comments received during the PC are addressed in Appendix&#x000a0;<xref rid="efs29470-app-0001" ref-type="app">A</xref>.</p></sec></sec><sec id="efs29470-sec-0016"><label>3</label><title>ASSESSMENT</title><sec id="efs29470-sec-0017"><label>3.1</label><title>Characterisation of the food/constituent</title><p>The food constituent proposed by the applicant as the subject of the health claim is &#x02018;phenolic compounds naturally present in virgin olive oil&#x02019;.</p><p>In European legislation,<xref rid="efs29470-note-1006" ref-type="fn">
<sup>4</sup>
</xref> phenolic compounds are not among the parameters included in the specifications for the categorisation and grading of olive oil and olive&#x02010;pomace oil, and therefore, virgin olive oil is not characterised on the basis of its phenolic content. In the context of the scientific evidence submitted for the substantiation of the claim (Section&#x000a0;<xref rid="efs29470-sec-0019" ref-type="sec">3.3</xref>), the Panel understands that the food constituent that is the subject of the health claim is phenolic compounds naturally present in olive oil.</p><p>The applicant specifies that the term phenolic compounds encompass both olive oil polyphenols and monophenolic compounds, such as oleocanthal.</p><p>Polyphenols are a diverse group of secondary plant metabolites, comprising several thousand compounds, including flavonoids, isoflavonoids, phenolic acids, proanthocyanidins, tannins and lignans, each with distinct biological activities. The major phenolic compounds in olive oil are simple phenols (e.g. hydroxytyrosol and tyrosol), secoiridoids (e.g. oleuropein, ligstroside and their key derivatives such as oleacein and oleocanthal) and lignans (e.g. pinoresinol). The total phenolic content in olive oil can be quantified using established analytical methods, such as the Folin&#x02013;Ciocalteu spectrophotometric (colorimetric) assay (Singleton &#x00026; Rossi,&#x000a0;<xref rid="efs29470-bib-0038" ref-type="bibr">1965</xref>). In the Folin&#x02013;Ciocalteu assay applied to olive oil, the most commonly used standard is gallic acid, with results generally expressed as gallic acid equivalents (GAE). However, alternative standards such as caffeic acid have also been used. In a previous assessment, the Panel noted that the Folin&#x02013;Ciocalteu method is not suitable for characterising polyphenols in foods in general due to its lack of specificity, as it measures all reducing compounds (e.g. sugars, ascorbic acid and proteins) and thereby can overestimate polyphenol content (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0006" ref-type="bibr">2011</xref>). However, the olive oil matrix inherently lacks significant amounts of these interfering compounds, making the Folin&#x02013;Ciocalteu assay an appropriate and reliable method for quantifying phenolic compounds in olive oil, as supported by Reboredo&#x02010;Rodr&#x000ed;guez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0031" ref-type="bibr">2016</xref>).</p><p>For detailed characterisation of individual phenolic compounds (e.g. hydroxytyrosol, oleuropein or ligstroside derivatives), high&#x02010;performance liquid chromatography (HPLC) coupled with UV detection is commonly employed. For enhanced sensitivity and specificity in quantifying specific phenols, particularly at low concentrations (e.g. oleocanthal, oleacein), HPLC with tandem mass spectrometry (HPLC&#x02010;MS/MS) is typically used.</p><p>The applicant suggests that phenolic compounds in olive oil should be quantified by the International Olive Council (IOC) certified method 1 (COI/T.20/Doc. No 29/Rev.12017). This method is based on the direct extraction of the minor polar phenolic compounds from olive oil by means of a methanol solution and subsequent quantification by HPLC with the aid of a UV detector at 280 nm. Following normalisation to the internal standard (syringic acid), the content of the natural and oxidised oleuropein and ligustroside derivatives, lignans, flavonoids and phenolic acids is expressed in mg/kg of tyrosol equivalents (tyrosol used as the external standard). The range of measurement is from 30 mg/kg to 800 mg/kg.</p><p>The Panel considers that the food/constituent phenolic compounds naturally present in olive oil, which is the subject of the health claim, are sufficiently characterised.</p></sec><sec id="efs29470-sec-0018"><label>3.2</label><title>Relevance of the claimed effect to human health</title><p>The claimed effect proposed by the applicant is the lowering of blood LDL&#x02010;cholesterol and systolic blood pressure, risk factors for coronary heart disease. The proposed target population is the general healthy population, including subgroups with mildly raised LDL&#x02010;c and/or blood pressure.</p><p>As stated in the Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0007" ref-type="bibr">2018</xref>), elevated blood LDL&#x02010;cholesterol concentration and elevated arterial systolic blood pressure (SBP) are independently associated with an increased risk of coronary heart disease (CHD) and lowering LDL&#x02010;cholesterol concentration and/or SBP would generally reduce the risk of CHD. Therefore, the scientific substantiation of claims relating to a reduced risk of CHD can be based on evidence of a reduction in either blood LDL&#x02010;cholesterol concentration or arterial SBP, and evidence of a reduction in the incidence of CHD is not required.</p><p>Regarding the study duration, blood lipids and blood pressure tend to stabilise after about 4&#x02009;weeks in response to nutritional interventions. However, the time needed to reach such stabilisation may depend on the study characteristics (e.g. appropriate run&#x02010;in period) and the nature of the intervention. Evidence on the sustainability of the effect with continuous consumption of the food/constituent over longer periods of time (e.g. &#x02265;&#x02009;8&#x02009;weeks) should be provided (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0007" ref-type="bibr">2018</xref>).</p><p>The Panel considers that lowering of blood LDL&#x02010;cholesterol and systolic blood pressure is a beneficial effect by reducing the risk of CHD.</p></sec><sec id="efs29470-sec-0019"><label>3.3</label><title>Scientific substantiation of the claimed effect</title><p>The NDA Panel has previously evaluated a health claim under article 13(1) of Regulation (EC) No 1924/2006 on polyphenols in olive and the maintenance of normal blood pressure with a negative outcome. The Panel could not draw conclusions for the scientific substantiation of the claimed effect from any of the human intervention studies submitted (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0006" ref-type="bibr">2011</xref>). No health claims related to phenolic compounds in olive oil and the maintenance of normal blood LDL&#x02010;c concentration or reduction of LDL&#x02010;c concentration as a risk factor for CHD have been previously assessed by EFSA.</p><p>In the current application, the applicant first aimed to identify systematic reviews registered in PROSPERO using the term &#x02018;virgin olive oils&#x02019; and for which the results were already published in a peer&#x02010;reviewed journal. The applicant identified two published systematic reviews and meta&#x02010;analyses of human intervention studies investigating the effect of olive oil polyphenols on cardiovascular risk factors (George et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0017" ref-type="bibr">2019</xref>; Schwingshackl et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0037" ref-type="bibr">2019</xref>). The applicant assumed that these publications could encompass all human intervention studies pertinent to the claim published until December 2018. Therefore, the applicant performed a literature search in the database PubMed from January 2019 to November 2023 to identify additional studies published after that date.</p><p>The full search strategy with keywords was provided by the applicant. The eligibility criteria for inclusion were randomised controlled clinical trials (RCT) conducted in healthy and non&#x02010;healthy humans with a study duration of at least 3&#x02009;weeks, reporting the effects of olive oil phenolic compounds on at least one of the following parameters: blood concentrations of total cholesterol (TC), HDL&#x02010;cholesterol (HDL&#x02010;c) or LDL&#x02010;cholesterol (LDL&#x02010;c); systolic blood pressure (SBP) or diastolic blood pressure (DBP). Only studies reporting the content of phenols in the olive oils tested and comparing with oils without phenols or with different doses were considered. Studies reporting blood lipid and/or blood pressure values at the end of the intervention only, and not changes over time, were excluded. The systematic reviews identified were scrutinised for additional relevant references that may have been omitted by the search.</p><p>A total of 11 articles, reporting on seven studies, were identified by the applicant as being pertinent to the claim. Of these, eight articles were identified via the two published systematic reviews (Al&#x02010;Rewashdeh,&#x000a0;<xref rid="efs29470-bib-0001" ref-type="bibr">2010</xref>; Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>; Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>; Gimeno et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0018" ref-type="bibr">2007</xref>; Hern&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0019" ref-type="bibr">2015</xref>; Marrugat et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>; Perona et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0028" ref-type="bibr">2011</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>) and three articles via the systematic review they conducted (Khandouzi et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0020" ref-type="bibr">2021</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>).</p><p>The study by Al&#x02010;Rewashdeh&#x000a0;(<xref rid="efs29470-bib-0001" ref-type="bibr">2010</xref>) is a sequential, non&#x02010;randomised intervention study where 25 adult men and women consumed olive oils containing low, medium, or high phenolic content for 4&#x02009;weeks each, with a 4&#x02010;week washout period in between. All participants were instructed to consume the olive oils in the same order ad&#x000a0;libitum in replacement of their usual fat intake. Olive oil consumption was assessed using weekly 3&#x02010;day diet recalls and food frequency questionnaires and was reported as an average intake over the study duration for the three intervention periods. Measures of LDL&#x02010;c concentration and SBP were also reported as averages for the three interventions and related washout periods. The Panel notes the sequential non&#x02010;randomised study design and that the information provided does not allow for accurate quantification of the amount of olive oil phenolic compounds consumed by participants during each intervention, nor does it allow for conclusions to be drawn about the independent effects of olive oil polyphenols on blood LDL&#x02010;c concentrations or SBP.</p><p>In the parallel, open&#x02010;label, RCT by Khandouzi et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0020" ref-type="bibr">2021</xref>), 50 patients with at least one cardiovascular risk factor and undergoing coronary angiography were randomly allocated to receive 25 mL/day of olive oil with either high or low polyphenol content for 6&#x02009;weeks (<italic toggle="yes">n</italic>&#x02009;=&#x02009;25 per group). The primary outcome of the study was plasma concentrations of IL&#x02010;6. Other inflammatory markers (both plasma concentrations and their production from whole blood culture), changes in body weight, the blood lipid profile and plasma concentrations of malondialdehyde were also assessed. A total of 40 patients (20 per group) completed the study (20% attrition rate). Reasons for withdrawal and compliance with the intervention in completers were not reported. The statistical analyses were conducted in completers only, of which 95% (19 per group) were on statins and did not account for multiplicity of outcomes. The Panel notes the significant methodological limitations of the study (i.e. participants and assessors were not blinded, high attrition rate, unknown compliance with the intervention, statistical analyses in completers only were not adjusted for multiple testing).</p><p>The study by Hern&#x000e1;ez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0019" ref-type="bibr">2015</xref>) presents the results of several LDL&#x02010;c particle&#x02010;related analyses in blood samples from a subset of volunteers (<italic toggle="yes">n</italic>&#x02009;=&#x02009;25) who participated in the EUROLIVE study (<italic toggle="yes">n</italic>&#x02009;=&#x02009;200), including blood LDL&#x02010;c concentrations. However, blood lipid profile parameters for the entire EUROLIVE study population, including changes in LDL&#x02010;c concentrations, are reported in another publication also submitted in this application (Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>). The Panel notes that, although blood LDL&#x02010;c concentrations were directly measured and not calculated as in Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>), this study does not provide additional information regarding the claimed effect beyond what is reported in Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>) for the entire EUROLIVE sample.</p><p>Similarly, as noted also by the applicant, three publications (Gimeno et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0018" ref-type="bibr">2007</xref>; Marrugat et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>; Perona et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0028" ref-type="bibr">2011</xref>) reported on the same study, two of which provided information on LDL&#x02010;c particle&#x02010;related analyses only (Gimeno et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0018" ref-type="bibr">2007</xref>; Perona et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0028" ref-type="bibr">2011</xref>). The Panel considers that these two publications do not provide additional information regarding the claimed effect beyond what is reported in the original publication (Marrugat et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>).</p><p>For the reasons outlined above, the Panel considers that no conclusions can be drawn from 5 (Al&#x02010;Rewashdeh,&#x000a0;<xref rid="efs29470-bib-0001" ref-type="bibr">2010</xref>; Gimeno et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0018" ref-type="bibr">2007</xref>; Hern&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0019" ref-type="bibr">2015</xref>; Khandouzi et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0020" ref-type="bibr">2021</xref>; Perona et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0028" ref-type="bibr">2011</xref>) of the 11 publications provided by the applicant as being pertinent for the scientific substantiation of the claim. The remaining six studies are discussed later in this section.</p><p>In addition to the pertinent studies, the applicant submitted six human intervention studies as being supportive of the claim. Of these, four studies do not allow conclusions to be drawn for the scientific substantiation of the claim because they either:
<list list-type="alpha-lower" id="efs29470-list-0002"><list-item id="efs29470-li-0004"><p>reported on the effect of an olive oil with high polyphenol content only (single&#x02010;arm, uncontrolled study (Otrante et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0027" ref-type="bibr">2021</xref>)),</p></list-item><list-item id="efs29470-li-0005"><p>reported results from the EUROLIVE study stratified by geographical region for the three olive oil intervention arms (i.e. with different polyphenol content) combined (Bondia&#x02010;Pons et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0003" ref-type="bibr">2007</xref>) or</p></list-item><list-item id="efs29470-li-0006"><p>investigated the effect of olive oils with unknown polyphenol content in the context of other dietary interventions versus low&#x02010;fat diets without controlling for the co&#x02010;interventions or the fat quality/content of the control diet (the PREDIMED and CORDIOPREV studies, with several publications submitted).</p></list-item></list>
</p><p>The remaining two studies reported in three publications (Fit&#x000f3; et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0015" ref-type="bibr">2005</xref>; Fit&#x000f3; et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0016" ref-type="bibr">2008</xref>; Moreno&#x02010;Luna et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0025" ref-type="bibr">2012</xref>) assessed the effect of olive oil polyphenols per se (i.e. compared the effect of similar amounts of olive oil with different polyphenol content under similar conditions).</p><p>The first study (Fit&#x000f3; et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0015" ref-type="bibr">2005</xref>; Fit&#x000f3; et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0016" ref-type="bibr">2008</xref>) was a randomised, placebo&#x02010;controlled, crossover study in 46 patients on secondary prevention for CHD. Participants consumed 50 mL/day of olive oil with either high (161 mg/kg measured by HPLC, providing approximately 7.4 mg/day of polyphenols) or low (14 mg/kg, providing approximately 0.6 mg/day of polyphenols) polyphenol content. Each intervention phase lasted 3&#x02009;weeks, separated by a 2&#x02010;week washout period during which all participants received the low&#x02010;polyphenol olive oil. The declared primary outcomes were plasma concentrations of phenolic compounds and oxidative stress (no sample size calculations were provided). A secondary objective was to assess blood pressure (BP) in hypertensive individuals with stable CHD. The blood lipid profile was also measured. A total of three patients withdrew for reasons unrelated to the intervention and three patients were non&#x02010;compliant. Of the 40 patients for whom data were provided, all were on aspirin, 33 were on statins, 20 on ACE&#x02010;inhibitors, 26 on beta&#x02010;blockers, 11 on long&#x02010;acting nitrates and 11 on calcium channel antagonists. The Panel notes that, except for the long&#x02010;acting nitrates, aspirin and statins, all other pharmacological therapies are used in the management of hypertension. Changes in BP during the study were only reported for 19 subjects with a diagnosis of hypertension at baseline, and a subgroup analysis was provided according to baseline SBP &#x02265;&#x02009;140&#x02009;mm Hg (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9) or &#x0003c;&#x02009;140&#x02009;mm Hg (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10). The criteria used to establish the diagnosis of hypertension and the selection process for these 19 subjects were not defined. The authors reported a significant decrease in SBP during the high versus the low olive oil polyphenol consumption, which was restricted to patients with SBP &#x02265;&#x02009;140&#x02009;mmHg at baseline on subgroup analysis, and no between&#x02010;period differences in DBP. The authors also reported that no period (time) effect, intervention&#x02010;period interaction or interaction with medical treatments were observed. Considering that at least 20 patients were on ACE&#x02010;inhibitors and that half of the 19 hypertensive subjects had SBP above the therapeutic target, it is unclear how these 19 patients were selected from the sample of 40, whether all patients were on pharmacological treatment for hypertension or not, how they were distributed between the intervention sequences or how the interaction with medical treatments was tested for such a small sample size. Changes in the blood lipid profile were reported for all 40 subjects, 33 of whom were on statins. No changes in blood LDL&#x02010;c concentrations were observed. The Panel notes that this study is at high risk of selective reporting and considers that no conclusions can be drawn for the scientific substantiation of the claim.</p><p>The second study (Moreno&#x02010;Luna et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0025" ref-type="bibr">2012</xref>) was a randomised, crossover intervention in young women (mean age: 27&#x02009;years) with high&#x02010;normal blood pressure (SBP of 120&#x02013;139&#x02009;mm Hg or DBP of 80&#x02013;89&#x02009;mmHg) or stage 1 essential hypertension (SBP of 140&#x02013;159&#x02009;mmHg DBP of 90&#x02013;99&#x02009;mmHg) not on pharmacological treatment for hypertension. The Panel considers that the results obtained in this study group could be extrapolated to the target population for which the claim is intended (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0007" ref-type="bibr">2018</xref>). Forty women meeting the inclusion criteria were consecutively sampled, of which six refused enrolment. Following a 4&#x02010;month run&#x02010;in on a standardised Mediterranean&#x02010;style diet, participants were randomised and underwent two 2&#x02010;month intervention periods (separated by a 4&#x02010;week washout) during which they consumed 60 mL/day of olive oil with either a high polyphenol content (total polyphenols 564 mg/kg measured by reverse&#x02010;phase HPLC&#x02010;DAD, providing approximately 31 mg/day of polyphenols) or no polyphenols. Compliance with the intervention was assessed using daily food records. It is unclear from the publication whether the study was planned as single or double blind (contradictory information in the abstract, materials and methods and discussion). Furthermore, the authors acknowledged that it could have been unblinded owing to the strong taste of the olive oil high in polyphenols.</p><p>At the end of each intervention period, BP and endothelial function were measured and blood samples were collected for the indirect determination of plasma nitric oxide (via total nitrites/nitrates) and ox&#x02010;LDL concentrations, as well as for asymmetric dimethylarginine (ADMA) and hs&#x02010;CRP concentrations in serum. Peripheral (brachial) SBP and DBP were measured in the right arm after 10 minutes in a supine position three times at 2&#x02010;minute intervals using an automated oscillometric device. The mean of the three measurements was used for data analysis. It is unclear which was the primary outcome of the study, as sample size calculations were not reported.</p><p>Ten women withdrew after the first dietary intervention phase (six due to protocol violations, three due to oil intolerance and one due to relocation), leading to a 29% attrition rate. No information is provided about the characteristics of women dropping out. A total of 24 women completed the study. Statistical analyses were conducted in completers only. Changes after the polyphenol&#x02010;rich and polyphenol&#x02010;free olive oil diets with respect to the run&#x02010;in period (baseline values) were assessed using Student's <italic toggle="yes">t</italic>&#x02010;test for paired samples for normally distributed variables and the Wilcoxon paired rank test when variables were not normally distributed. It is unclear from the publication how differences between intervention periods were assessed (i.e. ANOVA is only mentioned in a footnote to Table&#x000a0;<xref rid="efs29470-tbl-0001" ref-type="table">B.1</xref>), or whether and how carry&#x02010;over effects were investigated. The Panel considers that, owing to the important methodological limitations (e.g. high drop&#x02010;out rate, statistical analyses in completers only, unclear how data were analysed in relation to comparisons between intervention periods) and poor reporting of the study (contradictory and incomplete information regarding blinding and data analysis), no conclusions can be drawn for the scientific substantiation of the claim.</p><p>As part of the evidence submitted for the mechanism by which olive oil polyphenols might reduce BP, the applicant provided a publication reporting on a random subsample (<italic toggle="yes">n</italic>&#x02009;=&#x02009;18) of the EUROLIVE study (Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>). This subsample was selected to investigate the effect of olive oil polyphenols on blood pressure&#x02010;related gene expression. The Panel notes that, among other parameters, this publication reports on changes in blood pressure within this subsample, an outcome not addressed in the Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>) publication analysing the entire EUROLIVE study population (<italic toggle="yes">n</italic>&#x02009;=&#x02009;200). The Panel considers this publication as pertinent to the scientific substantiation of the claim.</p><p>The main characteristics and results of the five studies submitted (reported in seven publications) that the Panel considers for the scientific substantiation of the claim are presented in Table&#x000a0;<xref rid="efs29470-tbl-0001" ref-type="table">B.1</xref>, Appendix&#x000a0;<xref rid="efs29470-app-0002" ref-type="app">B</xref>. All studies investigated changes in blood LDL&#x02010;c concentrations, and four studies investigated changes in BP. Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>) reported blood LDL&#x02010;c results for the entire EUROLIVE study population, while Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>) provided BP results for a random subsample of the EUROLIVE study. Sarapis et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>) and Sarapis et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>) reported results for BP and blood LDL&#x02010;cholesterol concentrations, respectively, from the same study.</p><p>The Panel notes that, with few exceptions (Marrugat et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>), these intervention studies report on the content of polyphenols (rather than total phenolic compounds) in the olive oils tested, and therefore, this term will be used for the description of the pertinent studies. The Panel also notes that the terms polyphenols and phenolic compounds are used interchangeably in some studies.</p><p>When the daily doses of olive oil polyphenols were not reported in the studies, they were calculated based on the polyphenol content per kilogram of oil and the daily dose of olive oil given in millilitres, assuming an olive oil density of 0.916 g/mL (FAO/WHO,&#x000a0;<xref rid="efs29470-bib-0011" ref-type="bibr">2024</xref>).</p><sec id="efs29470-sec-0021"><title>Human intervention studies on the effect of olive oil polyphenols on blood LDL&#x02010;c concentrations</title><p>In a randomised, double&#x02010;blind, crossover trial (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>), 33 hypercholesterolaemic individuals not on cholesterol&#x02010;lowering medication with a mean age of ~55&#x02009;years consumed 25 mL/day of either olive oil with low polyphenol content (80 mg/kg oil, 1.8 mg/day) or polyphenol&#x02010;enriched olive oil (500 mg/kg oil, 11.5 mg/day) for a 3&#x02010;week period, separated by a 2&#x02010;week washout interval. The Panel considers that the results of a third intervention arm involving olive oil enriched with both olive oil and thyme polyphenols are not pertinent to the claim under evaluation and will not be discussed further. The primary outcome of the study was the total HDL&#x02010;particle number. Plasma LDL&#x02010;c concentrations, calculated using the Friedewald equation, were a secondary outcome. The analytical method used to quantify the content of polyphenols in olive oil is not reported in the paper. The Panel notes that another publication (Farr&#x000e0;s et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0012" ref-type="bibr">2015</xref>) reported on the total phenolic content and the phenolic profile of the same olive oils used in this trial as assessed by the Folin&#x02013;Ciocalteu method and high&#x02010;performance liquid chromatography coupled to tandem mass spectrometry (HPLC/MS/MS), respectively. Compliance with the interventions was confirmed via measurement of 24&#x02010;hour urinary hydroxytyrosol sulfate using HPLC&#x02010;ESI&#x02010;MS/MS.</p><p>Between group differences in blood LDL&#x02010;c concentrations and SBP changes during the study were assessed by analysis of covariance (ANCOVA) with the following covariates: age, gender, sequence of olive oil administration, baseline LDL&#x02010;c concentrations and baseline SBP values. Consumption of polyphenol&#x02010;enriched olive oil significantly reduced LDL&#x02010;c concentrations compared to olive oil with low polyphenol content (mean change: &#x02212;13 mg/dL [95% CI: &#x02212;17, &#x02212;9.40] vs. +1 mg/dL [95% CI: &#x02212;3.2, 5.2], respectively). The between&#x02010;group difference in LDL&#x02010;c reduction was statistically significant (&#x02212;14 mg/dL [95% CI: &#x02212;20, &#x02212;8.6]; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><p>Four RCT crossover studies assessed the effect of olive oils with high and low polyphenol content on blood LDL&#x02010;c concentrations in healthy individuals. Three RCTs (Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>), all with a duration of the intervention of 3&#x02009;weeks and washout periods of 2&#x02009;weeks, with sample sizes ranging from 50 to 200 individuals, did not show a significant decrease in LDL&#x02010;c concentrations when comparing the high and low olive oil polyphenol interventions. Daily intake of polyphenols from olive oil ranged from 13.2 to 17.6 mg in the high polyphenol intervention and from 0.1 to 4.6 mg in the low polyphenol intervention. The fourth study did not test between&#x02010;group differences in blood LDL&#x02010;c concentrations (Marrugat et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>).</p><p>The Panel notes that one RCT in 33 hypercholesteraemic individuals showed a beneficial effect of olive oil polyphenols on blood LDL&#x02010;c concentrations when consumed at doses of 11.5 mg/day for 3&#x02009;weeks (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>), whereas no effect was observed in RCTs conducted in healthy individuals with larger sample sizes of up to 200 participants and daily olive oil polyphenol doses up to 17.6 mg (Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>). The Panel also notes that evidence on the sustainability of any potential effect on blood LDL&#x02010;c with continuous consumption of olive oil polyphenols over longer periods of time (e.g. &#x02265;&#x02009;8&#x02009;weeks) has not been provided (see Section&#x000a0;<xref rid="efs29470-sec-0018" ref-type="sec">3.2</xref>).</p></sec><sec id="efs29470-sec-0022"><title>Human intervention studies on the effect of olive oil polyphenols on blood pressure</title><p>Four of the crossover RCTs discussed above in relation to blood LDL&#x02010;c concentrations also assessed changes in BP (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>; Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>;Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>). Participants with hypertension were excluded at recruitment in all the studies and BP was not the primary outcome in any of them. Peripheral (brachial) BP was measured with a mercury sphygmomanometer after at least a ten&#x02010;minute rest in the seated position once (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>) or twice (average of two measurements (Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>)), except in one study (Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>) which measured both peripheral and central BP using a SphygmoCor XCEL device (mean of the last two out of three measurements) following a 5&#x02010;minute rest in the supine position. Pulse pressure (PP) was calculated as the difference between SBP and DBP in two studies (Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>). Sample size ranged from 18 to 58 individuals and the daily amount of olive oil polyphenols from 0.1 to 4.7 mg in the low polyphenol period and from 8.4 to 17.6 mg in the high polyphenol period. No significant differences between intervention periods were observed in any BP measurement in any of the studies considered, except for the study by Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>).</p><p>In the randomised, double&#x02010;blind, crossover trial conducted as a random subsample of the EUROLIVE study (Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>), 18 participants received 25 mL/day of olive oil with either high (366 mg/kg of oil) or low (2.7 mg/kg of oil) phenolic content (resulting in daily polyphenol intake of 8.4 and 0.1 mg/day respectively) for 3&#x02009;weeks, and with a 2&#x02010;week washout period in between the two interventions. Although the EUROLIVE study also included a third intervention period with olive oil containing medium phenolic content (164 mg/kg of oil, 3.8 mg/day), BP data for this intervention period were not reported in the publication. The primary outcome was the change in the expression of BP&#x02010;related genes in peripheral blood mononuclear cells.</p><p>Relative to baseline, the between&#x02010;group differences for mean changes (&#x000b1; SEM) in SBP (&#x02212;4.22&#x02009;&#x000b1;&#x02009;1.81&#x02009;mmHg and&#x02009;+&#x02009;0.44&#x02009;&#x000b1;&#x02009;1.81&#x02009;mmHg during the high and low olive oil polyphenol interventions, respectively), assessed using adjusted general linear mixed models, were not statistically significant (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.06). Mean change in DBP from baseline was statistically significantly different between the low and high olive oil polyphenol interventions (2.94&#x02009;&#x000b1;&#x02009;1.34&#x02009;mmHg vs. &#x02212;2.11&#x02009;&#x000b1;&#x02009;1.34&#x02009;mmHg, respectively; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.007). The Panel notes the small sample size of this study.</p><p>The Panel considers that the four crossover RCTs described above, which were all conducted in healthy, normotensive individuals, do not show an effect of olive oil polyphenols on SBP. The Panel also considers that some of these studies, with a sample size between 18 and 58 individuals, may have been underpowered to assess between&#x02010;group differences in BP changes, which were not the primary outcome in any of the studies.</p></sec><sec id="efs29470-sec-0023"><title>Mechanism of action</title><sec id="efs29470-sec-0024"><title>LDL&#x02010;cholesterol</title><p>The applicant suggested that phenolic compounds in olive oil could reduce LDL&#x02010;c concentrations by reducing systemic oxidative stress, which correlates with small and dense LDL particles prone to oxidation, by increasing lipoprotein lipase (LPL) activity and by up&#x02010;regulating cholesterol efflux.</p><p>In support of the mechanism of action, the applicant provided a cross&#x02010;sectional study reporting on the association between diacron reactive oxygen metabolites (d&#x02010;ROMs) and small and dense LDL particles (Kotani et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0022" ref-type="bibr">2012</xref>), a narrative review on the role of LPL on lipoprotein metabolism (Otarod &#x00026; Goldberg,&#x000a0;<xref rid="efs29470-bib-0026" ref-type="bibr">2004</xref>), a rat study on the relationship between the antioxidant capacity of plasma and LPL activity and lipoprotein metabolism following interventions with lipoic acid and N&#x02010;acetylcysteine (Yang et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0041" ref-type="bibr">2006</xref>), a narrative review on the mechanisms by which dietary polyphenols in general could decrease blood LDL&#x02010;c concentrations in humans (Sun et&#x000a0;al., <xref rid="efs29470-bib-0042" ref-type="bibr">2021</xref>) and a single dose, 5&#x02010;h human intervention with olive oil polyphenols on gene expression in which cholesterol efflux was not measured (Farr&#x000e0;s et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0013" ref-type="bibr">2013</xref>).</p><p>The Panel notes that, although olive oil polyphenols have been shown to decrease oxidative damage to LDL&#x02010;c particles in a dose&#x02013;response manner, this effect did not translate into changes in blood LDL&#x02010;c concentrations (Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>). The Panel also notes that no evidence has been provided for an effect of phenolic compounds on LPL activity or on cholesterol efflux.</p><p>The Panel considers that no evidence has been provided for a plausible mechanism by which phenolic compounds in olive oil could reduce blood LDL&#x02010;c in humans.</p></sec><sec id="efs29470-sec-0025"><title>Blood pressure</title><p>The applicant suggests that phenolic compounds in olive oil could reduce BP by inducing endothelium&#x02010;dependent vasodilation through the increased availability of nitric oxide metabolites (serum nitrites/nitrates, NOx) and endothelium&#x02010;derived hyperpolarising factor (EDHF) in blood vessels.</p><p>The applicant provided two crossover RCTs which investigated the effect of olive oil polyphenols on blood NOx concentrations and on endothelium&#x02010;dependent vasodilation using the ischaemic reactive hyperaemia (IRH) technique. In the first study (Ruano et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0032" ref-type="bibr">2005</xref>), 21 hypercholesterolaemic adults consumed breakfasts with 40 mL of olive oil, either high (400 mg/kg of oil, i.e. 14.7 mg) or low (80 mg/kg of oil, i.e. 2.9 mg) phenolic content. NOx was measured at 0, 30, 60, 120 and 240 min after consumption, and IRH at baseline and at 120 and 240 min after each meal. Both NOx and endothelium&#x02010;dependent vasodilation were significantly higher after the olive oil with the high versus the low polyphenol content in the 4 h after consumption of the meals. In a longer term study already described at the beginning of this section (Moreno&#x02010;Luna et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0025" ref-type="bibr">2012</xref>), a significant increase in NOx and endothelium&#x02010;dependent vasodilation was also reported in women with high&#x02010;normal BP or stage 1 untreated hypertension (<italic toggle="yes">n</italic>&#x02009;=&#x02009;24) after a period of 2 months consuming olive oil high in polyphenols (providing 31 mg/day of polyphenols), as compared to the 2&#x02010;month period in which they consumed an olive oil without polyphenols. SBP and DBP were reported to decrease accordingly during the high polyphenol period in these women. The Panel considers that, although no conclusions could be drawn from this small study for the scientific substantiation of an effect of olive oil polyphenols on BP owing to significant methodological limitations and poor reporting, it provides, together with the single meal study by Ruano et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0032" ref-type="bibr">2005</xref>), some evidence for a mechanism by which these compounds could mediate a reduction in BP.</p><p>In addition, the applicant also suggested that olive oil polyphenols may be involved in the expression of genes that play a role in the modulation of the renin&#x02013;angiotensin&#x02013;aldosterone system (RAAS). This hypothesis was tested in the study by Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>) described above in relation to BP. Olive oil polyphenols tended to decrease the expression of some genes involved in the modulation of the RAAS system in peripheral blood mononuclear cells, but differences between the high and low olive oil polyphenol interventions were not statistically significant, possibly owing to the small sample size of the study (<italic toggle="yes">n</italic>&#x02009;=&#x02009;18).</p><p>The Panel notes that other references submitted by the applicant are less relevant to this application. Two narrative reviews (Andriantsitohaina et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0002" ref-type="bibr">2012</xref>; Stoclet et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0039" ref-type="bibr">2004</xref>) provided in support of the proposed mechanisms address dietary polyphenols in general rather than olive oil polyphenols specifically. The applicant also cited several studies investigating the effects of olive leaf polyphenols, primarily oleuropein, on BP (de Bock et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0005" ref-type="bibr">2013</xref>; Perrinjaquet&#x02010;Moccetti et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0029" ref-type="bibr">2008</xref>; Rahimianfar,&#x000a0;<xref rid="efs29470-bib-0030" ref-type="bibr">2022</xref>). The Panel notes that the phenolic profile of olive leaf extracts differs from that of olive oils, with oleuropein being considerably more abundant in olive leaves, and that while these studies hypothesise mechanisms of action consistent with those suggested by the applicant, none of them provide direct experimental evidence validating these pathways.</p><p>The Panel considers that, whereas the applicant has provided some evidence that phenolic compounds in olive oil could increase NOx, endothelial&#x02010;mediated vasodilation, and possibly the expression of genes involved in the modulation of the RAAS, which are all well&#x02010;known mechanisms involved in the regulation of BP in humans, no evidence has been provided that these changes are consistently achieved upon consumption of olive oil phenolic compounds, or that the magnitude and/or duration of these changes effectively translate into a reduction of BP in&#x000a0;vivo in humans.</p><p>
<bold>Weight of evidence</bold>
</p><p>In weighing the evidence with regard to LDL&#x02010;c, the Panel took into account that, although one human intervention study in hypercholesterolaemic individuals showed a reduction in blood LDL&#x02010;c following daily consumption of olive oil polyphenols for 3&#x02009;weeks (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>), these results are not supported by other studies (Covas et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>) and have not been replicated in other population groups or settings. The Panel also took into account that no evidence was available for the sustainability of the effect with continuous consumption of olive oil polyphenols over longer periods of time (e.g. &#x02265;&#x02009;8&#x02009;weeks), and that no evidence for a plausible mechanism by which olive oil phenolic compounds could exert the claimed effect was provided.</p><p>In weighing the evidence with regard to SBP, the Panel took into account that, although some evidence for a plausible mechanism by which phenolic compounds could exert the claimed effect has been provided, the studies submitted for the scientific substantiation of the claimed effect did not show an effect of olive oil polyphenols on SBP (Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>; Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>; Sanchez&#x02010;Rodriguez et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>; Sarapis et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>).</p><p>The Panel concludes that a cause&#x02010;and&#x02010;effect relationship has not been established between the consumption of phenolic compounds in olive oil and the reduction of blood LDL&#x02010;c or SBP.</p></sec></sec></sec></sec><sec sec-type="conclusions" id="efs29470-sec-0026"><label>4</label><title>CONCLUSIONS</title><p>On the basis of the data presented, the Panel concludes that:
<list list-type="bullet" id="efs29470-list-0003"><list-item id="efs29470-li-0007"><p>The food/constituent, phenolic compounds naturally present in olive oil, which is the subject of the health claim, is sufficiently characterised.</p></list-item><list-item id="efs29470-li-0008"><p>The claimed effect proposed by the applicant is lowering of LDL&#x02010;cholesterol and systolic blood pressure. The target population proposed by the applicant is &#x02018;the general healthy and subgroup with mildly raised LDL&#x02010;c and blood pressure&#x02019;. The Panel considers that lowering of LDL&#x02010;cholesterol and systolic blood pressure are beneficial effects by reducing the risk of coronary heart disease.</p></list-item><list-item id="efs29470-li-0009"><p>A cause&#x02010;and&#x02010;effect relationship has not been established between the consumption of phenolic compounds naturally present in olive oil and the reduction of blood LDL&#x02010;c or SBP.</p></list-item></list>
</p></sec><sec id="efs29470-sec-0027"><label>5</label><title>DOCUMENTATION AS PROVIDED TO <styled-content style="fixed-case" toggle="no">EFSA</styled-content>
</title><p>Health claim application pursuant to Article 14 of Regulation (EC) No 1924/2006 (EFSA&#x02010;Q&#x02010;2024&#x02010;00470, HC&#x02010;2024&#x02010;22631). Submitted by QvExtra! Internacional.</p></sec><sec id="efs29470-sec-0028"><label>6</label><title>STEPS TAKEN BY <styled-content style="fixed-case" toggle="no">EFSA</styled-content>
</title><p>
<list list-type="order" id="efs29470-list-0004"><list-item id="efs29470-li-0010"><p>The application was received by EFSA on 16/07/2024. The application was validated on 09/10/2024, and the scientific evaluation started.</p></list-item><list-item id="efs29470-li-0011"><p>EFSA sent a first Additional Data Request (ADR) letter to the Applicant on 21/10/2024. The clock was stopped and restarted on 19/11/2024.</p></list-item><list-item id="efs29470-li-0012"><p>The application on was open for public consultation from 21/02/2025 to 14/03/2025 (<ext-link xlink:href="https://connect.efsa.europa.eu/RM/s/consultations/publicconsultation2/a0lTk000003mGjt/pc1329" ext-link-type="uri">PC&#x02010;1329</ext-link>).</p></list-item><list-item id="efs29470-li-0013"><p>During its meeting on 06/05/2025, the NDA Panel, having evaluated the data, adopted an opinion on the scientific substantiation of a health claim related to &#x0201c;Phenolic compounds naturally present in olive oil and lowering of blood LDL&#x02010;cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006&#x0201d;.</p></list-item></list>
</p></sec><sec id="efs29470-sec-0029"><title>REQUESTOR</title><p>Competent Authority of Spain following an application by QvExtra! Internacional.</p></sec><sec id="efs29470-sec-0030"><title>QUESTION NUMBER</title><p>EFSA&#x02010;Q&#x02010;2024&#x02010;00470</p></sec><sec id="efs29470-sec-0032"><title>COPYRIGHT FOR NON&#x02010;EFSA CONTENT</title><p>EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.</p></sec><sec id="efs29470-sec-0031"><title>PANEL MEMBERS</title><p>Dominique Turck, Torsten Bohn, Monta&#x000f1;a C&#x000e1;mara, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch&#x02010;Ernst, Angeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani and Frank Thies.</p></sec></body><back><ack id="efs29470-sec-1023"><title>ACKNOWLEDGEMENTS</title><p>EFSA wishes to acknowledge the contribution of WG on Claims: Stefaan de Henauw, Alfonso Siani, Frank Thies and Ines Drenjan&#x0010d;evi&#x00107; to this opinion. EFSA wishes to thank the contribution of the hearing expert Marina Heinonen.</p></ack><fn-group id="efs29209-ntgp-1342"><title>Notes</title><fn id="efs29470-note-1003"><label>
<sup>1</sup>
</label><p>Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1&#x02013;48.</p></fn><fn id="efs29470-note-1004"><label>
<sup>2</sup>
</label><p>Decision available at: <ext-link xlink:href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.efsa.europa.eu%2Fsites%2Fdefault%2Ffiles%2Fcorporate_publications%2Ffiles%2F210111-PAs-pre-submission-phase-and-public-consultations.pdf&#x00026;data=05%7C01%7C%7Cd475a92f61e3445fa10508dbb60b53b8%7C406a174be31548bdaa0acdaddc44250b%7C1%7C0%7C638303932000342413%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&#x00026;sdata=Xv6a0j5AvP9poWbdSwki9is7F6pwy1McjcSrXcEqnjo%3D&#x00026;reserved=0" ext-link-type="uri">https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/210111&#x02010;PAs&#x02010;pre&#x02010;submission&#x02010;phase&#x02010;and&#x02010;public&#x02010;consultations.pdf</ext-link>.</p></fn><fn id="efs29470-note-1005"><label>
<sup>3</sup>
</label><p>
<ext-link xlink:href="https://open.efsa.europa.eu/questions/EFSA-Q-2024-00470" ext-link-type="uri">https://open.efsa.europa.eu/questions/EFSA&#x02010;Q&#x02010;2024&#x02010;00470</ext-link>.</p></fn><fn id="efs29470-note-1006"><label>
<sup>4</sup>
</label><p>Commission delegated Regulation (EU) 2022/2104 of 29 July 2022 supplementing Regulation (EU) No 1308/2013 of the European Parliament and of the Council as regards marketing standards for olive oil, and repealing Commission Regulation (EEC) No 2568/91 and Commission Implementing Regulation (EU) No 29/2012. OJ L 284, 4.11.2022, p. 1.</p></fn></fn-group><ref-list content-type="cited-references" id="efs29470-bibl-0001"><title>REFERENCES</title><ref id="efs29470-bib-0001"><mixed-citation publication-type="journal" id="efs29470-cit-0001">
<string-name>
<surname>Al&#x02010;Rewashdeh</surname>, <given-names>A. Y. A.</given-names>
</string-name> (<year>2010</year>). <article-title>Blood lipid profile, oxidation and pressure of men and women consumed olive oil</article-title>. <source>Pakistan Journal of Nutrition</source>, <pub-id pub-id-type="doi">10.3923/pjn.2010.15.26</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0002"><mixed-citation publication-type="journal" id="efs29470-cit-0002">
<string-name>
<surname>Andriantsitohaina</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Auger</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chataigneau</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>&#x000c9;tienne&#x02010;Selloum</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;nez</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Schini&#x02010;Kerth</surname>, <given-names>V. B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Laher</surname>, <given-names>I.</given-names>
</string-name> (<year>2012</year>). <article-title>Molecular mechanisms of the cardiovascular protective effects of polyphenols</article-title>. <source>The British Journal of Nutrition</source>, <volume>108</volume>, <fpage>1532</fpage>&#x02013;<lpage>1549</lpage>. <pub-id pub-id-type="doi">10.1017/s0007114512003406</pub-id>
<pub-id pub-id-type="pmid">22935143</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0003"><mixed-citation publication-type="journal" id="efs29470-cit-0003">
<string-name>
<surname>Bondia&#x02010;Pons</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;der</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Castellote</surname>, <given-names>A. I.</given-names>
</string-name>, <string-name>
<surname>Kaikkonen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Poulsen</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Gaddi</surname>, <given-names>A. V.</given-names>
</string-name>, <string-name>
<surname>Machowetz</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kiesewetter</surname>, <given-names>H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name> (<year>2007</year>). <article-title>Moderate consumption of olive oil by healthy European men reduces systolic blood pressure in non&#x02010;Mediterranean participants</article-title>. <source>The Journal of Nutrition</source>, <volume>137</volume>, <fpage>84</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1093/jn/137.1.84</pub-id>
<pub-id pub-id-type="pmid">17182805</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0004"><mixed-citation publication-type="journal" id="efs29470-cit-0004">
<string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Nyyss&#x000f6;nen</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Poulsen</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Kaikkonen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zunft</surname>, <given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Kiesewetter</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Gaddi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mursu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>B&#x000e4;umler</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Nascetti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Salonen</surname>, <given-names>J. T.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Virtanen</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Marrugat</surname>, <given-names>J.</given-names>
</string-name> (<year>2006</year>). <article-title>The effect of polyphenols in olive oil on heart disease risk factors: A randomized trial</article-title>. <source>Annals of Internal Medicine</source>, <volume>145</volume>(<issue>5</issue>), <fpage>333</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-145-5-200609050-00006</pub-id>
<pub-id pub-id-type="pmid">16954359</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0005"><mixed-citation publication-type="journal" id="efs29470-cit-0005">
<string-name>
<surname>de Bock</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Derraik</surname>, <given-names>J. G.</given-names>
</string-name>, <string-name>
<surname>Brennan</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Biggs</surname>, <given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>, <given-names>P. E.</given-names>
</string-name>, <string-name>
<surname>Hodgkinson</surname>, <given-names>S. C.</given-names>
</string-name>, <string-name>
<surname>Hofman</surname>, <given-names>P. L.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Cutfield</surname>, <given-names>W. S.</given-names>
</string-name> (<year>2013</year>). <article-title>Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle&#x02010;aged overweight men: A randomized, placebo&#x02010;controlled, crossover trial</article-title>. <source>PLoS One</source>, <volume>8</volume>(<issue>3</issue>), <elocation-id>e57622</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0057622</pub-id>
<pub-id pub-id-type="pmid">23516412</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0050"><mixed-citation publication-type="journal" id="efs29470-cit-0050">
<string-name>
<surname>de la Torre&#x02010;Carbot</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ch&#x000e1;vez&#x02010;Serv&#x000ed;n</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Ja&#x000fa;regui</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Castellote</surname>, <given-names>A. I.</given-names>
</string-name>, <string-name>
<surname>Lamuela&#x02010;Ravent&#x000f3;s</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Nurmi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Poulsen</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Gaddi</surname>, <given-names>A. V.</given-names>
</string-name>, <string-name>
<surname>Kaikkonen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zunft</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<surname>Kiesewetter</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name> (<year>2010</year>). <article-title>Elevated circulating LDL phenol levels in men who consumed virgin rather than refined olive oil are associated with less oxidation of plasma LDL</article-title>. <source>Journal of Nutrition</source>, <volume>140</volume>, <fpage>501</fpage>&#x02013;<lpage>508</lpage>. <ext-link xlink:href="https://10.3945/jn.109.112912" ext-link-type="uri">https://10.3945/jn.109.112912</ext-link>
<pub-id pub-id-type="pmid">20089783</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0006"><mixed-citation publication-type="journal" id="efs29470-cit-0006">
<collab collab-type="authors">EFSA NDA Panel (Panel on Dietetic Products Nutrition and Allergies)</collab>
. (<year>2011</year>). <article-title>Scientific Opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), &#x0201c;anti&#x02010;inflammatory properties&#x0201d; (ID 1882), &#x0201c;contributes to the upper respiratory tract health&#x0201d; (ID 3468), &#x0201c;can help to maintain a normal function of gastrointestinal tract&#x0201d; (3779), and &#x0201c;contributes to body defences against external agents&#x0201d; (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/2006</article-title>. <source>EFSA Journal</source>, <volume>9</volume>(<issue>4</issue>), <elocation-id>2033</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2011.2033</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0007"><mixed-citation publication-type="journal" id="efs29470-cit-0007">
<collab collab-type="authors">EFSA NDA Panel (Panel on Dietetic Products Nutrition and Allergies)</collab>
. (<year>2018</year>). <article-title>Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health</article-title>. <source>EFSA Journal</source>, <volume>16</volume>(<issue>1</issue>), <elocation-id>5136</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2018.5136</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0008"><mixed-citation publication-type="journal" id="efs29470-cit-0008">
<collab collab-type="authors">EFSA NDA Panel (Panel on Dietetic Products Nutrition and Allergies)</collab>
. (<year>2021a</year>). <article-title>General scientific guidance for stakeholders on health claim applications (revision 1)</article-title>. <source>EFSA Journal</source>, <volume>19</volume>(<issue>3</issue>), <elocation-id>6553</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2021.6553</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0009"><mixed-citation publication-type="journal" id="efs29470-cit-0009">
<collab collab-type="authors">EFSA NDA Panel (Panel on Dietetic Products Nutrition and Allergies)</collab>
. (<year>2021b</year>). <article-title>Scientific and technical guidance for the preparation and presentation of a health claim application (revision 3)</article-title>. <source>EFSA Journal</source>, <volume>19</volume>(<issue>3</issue>), <elocation-id>6554</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2021.6554</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0010"><mixed-citation publication-type="journal" id="efs29470-cit-0010">
<collab collab-type="authors">EFSA NDA Panel (Panel on Nutrition, Novel Foods. Food Allergens)</collab>
. (<year>2025</year>). <article-title>Olive oil polyphenols and the maintenance of normal HDL&#x02010;cholesterol concentrations: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006</article-title>. <source>EFSA Journal</source>, <volume>23</volume>(<issue>5</issue>), <elocation-id>9372</elocation-id>. <pub-id pub-id-type="doi">10.2903/j.efsa.2025.9372</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0011"><mixed-citation publication-type="miscellaneous" id="efs29470-cit-0011">
<collab collab-type="authors">FAO/WHO (Food and Agriculture Organization of the United Nations and World Health Organization)</collab>
. (<year>2024</year>). <article-title>Codex Standard for Olive Oils and Olive&#x02010;Pomace Oils, CXS 33&#x02013;1981</article-title>. <ext-link xlink:href="https://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&#x00026;url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXS%2B33-1981%252FCXS_033e.pdf" ext-link-type="uri">https://www.fao.org/fao&#x02010;who&#x02010;codexalimentarius/sh&#x02010;proxy/en/?lnk=1&#x00026;url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXS%2B33&#x02010;1981%252FCXS_033e.pdf</ext-link>
</mixed-citation></ref><ref id="efs29470-bib-0012"><mixed-citation publication-type="journal" id="efs29470-cit-0012">
<string-name>
<surname>Farr&#x000e0;s</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Casta&#x000f1;er</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;n&#x02010;Pel&#x000e1;ez</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ez</surname>, <given-names>&#x000c1;.</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;der</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Subirana</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Aguayo</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Gaixas</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Torre</surname>, <given-names>R. L.</given-names>
</string-name>, <string-name>
<surname>Farr&#x000e9;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rubi&#x000f3;</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>D&#x000ed;az</surname>, <given-names>&#x000d3;.</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Castillejo</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sol&#x000e0;</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Motilva</surname>, <given-names>M. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Complementary phenol&#x02010;enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double&#x02010;blind, crossover, controlled trial. The VOHF study</article-title>. <source>Molecular Nutrition &#x00026; Food Research</source>, <volume>59</volume>(<issue>9</issue>), <fpage>1758</fpage>&#x02013;<lpage>1770</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201500030</pub-id>
<pub-id pub-id-type="pmid">26011257</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0013"><mixed-citation publication-type="journal" id="efs29470-cit-0013">
<string-name>
<surname>Farr&#x000e0;s</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Valls</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Castillejo</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Giralt</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sol&#x000e0;</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Subirana</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Motilva</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Konstantinidou</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>). <article-title>Olive oil polyphenols enhance the expression of cholesterol efflux related genes in&#x000a0;vivo in humans. A randomized controlled trial</article-title>. <source>The Journal of Nutritional Biochemistry</source>, <volume>24</volume>, <fpage>1334</fpage>&#x02013;<lpage>1339</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2012.10.008</pub-id>
<pub-id pub-id-type="pmid">23333095</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0014"><mixed-citation publication-type="journal" id="efs29470-cit-0014">
<string-name>
<surname>Fern&#x000e1;ndez&#x02010;Castillejo</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Valls</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Casta&#x000f1;er</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Rubi&#x000f3;</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Catal&#x000e1;n</surname>, <given-names>&#x000da;.</given-names>
</string-name>, <string-name>
<surname>Pedret</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Maci&#x000e0;</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sampson</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Motilva</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Remaley</surname>, <given-names>A. T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Sol&#x000e0;</surname>, <given-names>R.</given-names>
</string-name> (<year>2016</year>). <article-title>Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, controlled trial</article-title>. <source>Molecular Nutrition &#x00026; Food Research</source>, <volume>60</volume>, <fpage>1544</fpage>&#x02013;<lpage>1554</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201501068</pub-id>
<pub-id pub-id-type="pmid">26992050</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0015"><mixed-citation publication-type="journal" id="efs29470-cit-0015">
<string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cladellas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Alc&#x000e1;ntara</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pujadas&#x02010;Bastardes</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marrugat</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bruguera</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Vila</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name> (<year>2005</year>). <article-title>Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: A randomized, crossover, controlled, clinical trial</article-title>. <source>Atherosclerosis</source>, <volume>181</volume>, <fpage>149</fpage>&#x02013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.12.036</pub-id>
<pub-id pub-id-type="pmid">15939067</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0016"><mixed-citation publication-type="journal" id="efs29470-cit-0016">
<string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cladellas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mart&#x000ed;</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;der</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Alc&#x000e1;ntara</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pujadas&#x02010;Bastardes</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marrugat</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Bruguera</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, &#x00026; <collab collab-type="authors">the members of the SI</collab>
. (<year>2008</year>). <article-title>Anti&#x02010;inflammatory effect of virgin olive oil in stable coronary disease patients: A randomized, crossover, controlled trial</article-title>. <source>European Journal of Clinical Nutrition</source>, <volume>62</volume>(<issue>4</issue>), <fpage>570</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejcn.1602724</pub-id>
<pub-id pub-id-type="pmid">17375118</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0017"><mixed-citation publication-type="journal" id="efs29470-cit-0017">
<string-name>
<surname>George</surname>, <given-names>E. S.</given-names>
</string-name>, <string-name>
<surname>Marshall</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>, <given-names>H. L.</given-names>
</string-name>, <string-name>
<surname>Trakman</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Tatucu&#x02010;Babet</surname>, <given-names>O. A.</given-names>
</string-name>, <string-name>
<surname>Lassemillante</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Bramley</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Forsyth</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Tierney</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Itsiopoulos</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Marx</surname>, <given-names>W.</given-names>
</string-name> (<year>2019</year>). <article-title>The effect of high&#x02010;polyphenol extra virgin olive oil on cardiovascular risk factors: A systematic review and meta&#x02010;analysis</article-title>. <source>Critical Reviews in Food Science and Nutrition</source>, <volume>59</volume>, <fpage>2772</fpage>&#x02013;<lpage>2795</lpage>. <pub-id pub-id-type="doi">10.1080/10408398.2018.1470491</pub-id>
<pub-id pub-id-type="pmid">29708409</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0018"><mixed-citation publication-type="journal" id="efs29470-cit-0018">
<string-name>
<surname>Gimeno</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>de la Torre&#x02010;Carbot</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Lamuela&#x02010;Ravent&#x000f3;s</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Castellote</surname>, <given-names>A. I.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, &#x00026; <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name> (<year>2007</year>). <article-title>Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial</article-title>. <source>British Journal of Nutrition</source>, <volume>98</volume>, <fpage>1243</fpage>&#x02013;<lpage>1250</lpage>. <pub-id pub-id-type="doi">10.1017/s0007114507778698</pub-id>
<pub-id pub-id-type="pmid">17617938</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0019"><mixed-citation publication-type="journal" id="efs29470-cit-0019">
<string-name>
<surname>Hern&#x000e1;ez</surname>, <given-names>&#x000c1;.</given-names>
</string-name>, <string-name>
<surname>Remaley</surname>, <given-names>A. T.</given-names>
</string-name>, <string-name>
<surname>Farr&#x000e0;s</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Castillejo</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Subirana</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;der</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Mampel</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Aguayo</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sampson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sol&#x000e0;</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Farr&#x000e9;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M.&#x02010;C.</given-names>
</string-name>, <string-name>
<surname>Nyyss&#x000f6;nen</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Zunft</surname>, <given-names>H.&#x02010;J. F.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M.&#x02010;I.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Olive oil polyphenols decrease LDL concentrations and LDL atherogenicity in men in a randomized controlled Trial1, 2, 3</article-title>. <source>The Journal of Nutrition</source>, <volume>145</volume>, <fpage>1692</fpage>&#x02013;<lpage>1697</lpage>. <pub-id pub-id-type="doi">10.3945/jn.115.211557</pub-id>
<pub-id pub-id-type="pmid">26136585</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0020"><mixed-citation publication-type="journal" id="efs29470-cit-0020">
<string-name>
<surname>Khandouzi</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zahedmehr</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Nasrollahzadeh</surname>, <given-names>J.</given-names>
</string-name> (<year>2021</year>). <article-title>Effect of polyphenol&#x02010;rich extra&#x02010;virgin olive oil on lipid profile and inflammatory biomarkers in patients undergoing coronary angiography: A randomised, controlled, clinical trial</article-title>. <source>International Journal of Food Sciences and Nutrition</source>, <volume>72</volume>, <fpage>548</fpage>&#x02013;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1080/09637486.2020.1841123</pub-id>
<pub-id pub-id-type="pmid">33121297</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0021"><mixed-citation publication-type="journal" id="efs29470-cit-0021">
<string-name>
<surname>Konstantinidou</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Aguayo</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Khymenets</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Saez</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Tormos</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Toledo</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Marti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ruiz&#x02010;Guti&#x000e9;rrez</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Ruiz Mendez</surname>, <given-names>M. V.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fito</surname>, <given-names>M.</given-names>
</string-name> (<year>2010</year>). <article-title>In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: A randomized controlled trial</article-title>. <source>The FASEB Journal</source>, <volume>24</volume>(<issue>7</issue>), <fpage>2546</fpage>&#x02013;<lpage>2557</lpage>. <pub-id pub-id-type="doi">10.1096/fj.09-148,452</pub-id>
<pub-id pub-id-type="pmid">20179144</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0022"><mixed-citation publication-type="journal" id="efs29470-cit-0022">
<string-name>
<surname>Kotani</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tsuzaki</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sakane</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Taniguchi</surname>, <given-names>N.</given-names>
</string-name> (<year>2012</year>). <article-title>The correlation between small dense LDL and reactive oxygen metabolites in a physical activity intervention in hyperlipidemic subjects</article-title>. <source>Journal of Clinical Medical Research</source>, <volume>4</volume>, <fpage>161</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.4021/jocmr870w</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0023"><mixed-citation publication-type="journal" id="efs29470-cit-0023">
<string-name>
<surname>Marrugat</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;der</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mir&#x000f3;&#x02010;Casas</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Gimeno</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Sabater</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Farr&#x000e9;</surname>, <given-names>M.</given-names>
</string-name> (<year>2004</year>). <article-title>Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation&#x02013;a randomized controlled trial</article-title>. <source>European Journal of Nutrition</source>, <volume>43</volume>(<issue>3</issue>), <fpage>140</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1007/s00394-004-0452-8</pub-id>
<pub-id pub-id-type="pmid">15168036</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0024"><mixed-citation publication-type="journal" id="efs29470-cit-0024">
<string-name>
<surname>Mart&#x000ed;n&#x02010;Pel&#x000e1;ez</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Casta&#x000f1;er</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Konstantinidou</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Subirana</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Aguayo</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Blanchart</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Gaixas</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Farr&#x000e9;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;ez</surname>, <given-names>G. T.</given-names>
</string-name>, <string-name>
<surname>Nyyss&#x000f6;nen</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Zunft</surname>, <given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name> (<year>2017</year>). <article-title>Effect of olive oil phenolic compounds on the expression of blood pressure&#x02010;related genes in healthy individuals</article-title>. <source>European Journal of Nutrition</source>, <volume>56</volume>, <fpage>663</fpage>&#x02013;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1007/s00394-015-1110-z</pub-id>
<pub-id pub-id-type="pmid">26658900</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0025"><mixed-citation publication-type="journal" id="efs29470-cit-0025">
<string-name>
<surname>Moreno&#x02010;Luna</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Hernandez</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Miranda</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Costa</surname>, <given-names>A. F.</given-names>
</string-name>, <string-name>
<surname>Jimenez&#x02010;Jimenez</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Vallejo&#x02010;Vaz</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Muriana</surname>, <given-names>F. J.</given-names>
</string-name>, <string-name>
<surname>Villar</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Stiefel</surname>, <given-names>P.</given-names>
</string-name> (<year>2012</year>). <article-title>Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension</article-title>. <source>American Journal of Hypertension</source>, <volume>25</volume>, <fpage>1299</fpage>&#x02013;<lpage>1304</lpage>. <pub-id pub-id-type="doi">10.1038/ajh.2012.128</pub-id>
<pub-id pub-id-type="pmid">22914255</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0026"><mixed-citation publication-type="journal" id="efs29470-cit-0026">
<string-name>
<surname>Otarod</surname>, <given-names>J. K.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Goldberg</surname>, <given-names>I. J.</given-names>
</string-name> (<year>2004</year>). <article-title>Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk</article-title>. <source>Current Atherosclerosis Reports</source>, <volume>6</volume>, <fpage>335</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1007/s11883-004-0043-4</pub-id>
<pub-id pub-id-type="pmid">15296698</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0027"><mixed-citation publication-type="journal" id="efs29470-cit-0027">
<string-name>
<surname>Otrante</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Trigui</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Walha</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Berrougui</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Fulop</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Khalil</surname>, <given-names>A.</given-names>
</string-name> (<year>2021</year>). <article-title>Extra virgin olive oil prevents the age&#x02010;related shifts of the distribution of HDL subclasses and improves their functionality</article-title>. <source>Nutrients</source>, <volume>13</volume>, <elocation-id>2235</elocation-id>. <pub-id pub-id-type="doi">10.3390/nu13072235</pub-id>
<pub-id pub-id-type="pmid">34209930</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0028"><mixed-citation publication-type="journal" id="efs29470-cit-0028">
<string-name>
<surname>Perona</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ruiz&#x02010;Gutierrez</surname>, <given-names>V.</given-names>
</string-name> (<year>2011</year>). <article-title>Olive oil phenols modulate the triacylglycerol molecular species of human very low&#x02010;density lipoprotein. A randomized, crossover, controlled trial</article-title>. <source>Metabolism</source>, <volume>60</volume>, <fpage>893</fpage>&#x02013;<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2010.08.010</pub-id>
<pub-id pub-id-type="pmid">20934731</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0029"><mixed-citation publication-type="journal" id="efs29470-cit-0029">
<string-name>
<surname>Perrinjaquet&#x02010;Moccetti</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Busjahn</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Schmidlin</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bradl</surname>, <given-names>B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Aydogan</surname>, <given-names>C.</given-names>
</string-name> (<year>2008</year>). <article-title>Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins</article-title>. <source>Phytotherapy Research</source>, <volume>22</volume>, <fpage>1239</fpage>&#x02013;<lpage>1242</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2455</pub-id>
<pub-id pub-id-type="pmid">18729245</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0030"><mixed-citation publication-type="book" id="efs29470-cit-0030">
<string-name>
<surname>Rahimianfar</surname>, <given-names>F.</given-names>
</string-name> (<year>2022</year>). <part-title>The effect of olive leaf extract on systolic and diastolic blood pressure in adults: A systemic review and meta&#x02010;analysis</part-title>. In <person-group person-group-type="editor">
<string-name>
<given-names>T.</given-names>
<surname>Yonar</surname>
</string-name>
</person-group> (Ed.), <source>Olive cultivation</source>. <publisher-name>IntechOpen</publisher-name>.</mixed-citation></ref><ref id="efs29470-bib-0031"><mixed-citation publication-type="journal" id="efs29470-cit-0031">
<string-name>
<surname>Reboredo&#x02010;Rodr&#x000ed;guez</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Valli</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Bendini</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lecce</surname>, <given-names>G. D.</given-names>
</string-name>, <string-name>
<surname>Simal&#x02010;G&#x000e1;ndara</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Toschi</surname>, <given-names>T. G.</given-names>
</string-name> (<year>2016</year>). <article-title>A widely used spectrophotometric assay to quantify olive oil biophenols according to the health claim (EU reg. 432/2012)</article-title>. <source>European Journal of Lipid Science and Technology</source>, <volume>118</volume>, <fpage>1593</fpage>&#x02013;<lpage>1599</lpage>.</mixed-citation></ref><ref id="efs29470-bib-0032"><mixed-citation publication-type="journal" id="efs29470-cit-0032">
<string-name>
<surname>Ruano</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lopez&#x02010;Miranda</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fuentes</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Bellido</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Perez&#x02010;Martinez</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Lozano</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Jim&#x000e9;nez</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>P&#x000e9;rez Jim&#x000e9;nez</surname>, <given-names>F.</given-names>
</string-name> (<year>2005</year>). <article-title>Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients</article-title>. <source>Journal of the American College of Cardiology</source>, <volume>46</volume>, <fpage>1864</fpage>&#x02013;<lpage>1868</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.06.078</pub-id>
<pub-id pub-id-type="pmid">16286173</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0033"><mixed-citation publication-type="journal" id="efs29470-cit-0033">
<string-name>
<surname>Sanchez&#x02010;Rodriguez</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Lima&#x02010;Cabello</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Biel&#x02010;Glesson</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Navarro</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Calleja</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Roca</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Espejo&#x02010;Calvo</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Gil&#x02010;Extremera</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Soria&#x02010;Florido</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Fito</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Alche</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Martinez de Victoria</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Gil</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Mesa</surname>, <given-names>M. D.</given-names>
</string-name> (<year>2018</year>). <article-title>Effects of virgin olive oils differing in their bioactive compound contents on metabolic syndrome and endothelial functional risk biomarkers in healthy adults: A randomized double&#x02010;blind controlled trial</article-title>. <source>Nutrients</source>, <volume>10</volume>, <elocation-id>626</elocation-id>. <pub-id pub-id-type="doi">10.3390/nu10050626</pub-id>
<pub-id pub-id-type="pmid">29772657</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0034"><mixed-citation publication-type="journal" id="efs29470-cit-0034">
<string-name>
<surname>Santangelo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Filesi</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Var&#x000ec;</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Scazzocchio</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Filardi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Fogliano</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>D'Archivio</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Giovannini</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lenzi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Morano</surname>, <given-names>S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Masella</surname>, <given-names>R.</given-names>
</string-name> (<year>2016</year>). <article-title>Consumption of extra&#x02010;virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: A possible involvement of reduced levels of circulating visfatin</article-title>. <source>Journal of Endocrinological Investigation</source>, <volume>39</volume>, <fpage>1295</fpage>&#x02013;<lpage>1301</lpage>. <pub-id pub-id-type="doi">10.1007/s40618-016-0506-9</pub-id>
<pub-id pub-id-type="pmid">27344308</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0035"><mixed-citation publication-type="journal" id="efs29470-cit-0035">
<string-name>
<surname>Sarapis</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>George</surname>, <given-names>E. S.</given-names>
</string-name>, <string-name>
<surname>Marx</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>, <given-names>H. L.</given-names>
</string-name>, <string-name>
<surname>Willcox</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Powell</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Folasire</surname>, <given-names>O. S.</given-names>
</string-name>, <string-name>
<surname>Lohning</surname>, <given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Prendergast</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Itsiopoulos</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>C. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Moschonis</surname>, <given-names>G.</given-names>
</string-name> (<year>2023</year>). <article-title>Extra virgin olive oil improves HDL lipid fraction but not HDL&#x02010;mediated cholesterol efflux capacity: A double&#x02010;blind, randomised, controlled, cross&#x02010;over study (OLIVAUS)</article-title>. <source>The British Journal of Nutrition</source>, <volume>130</volume>, <fpage>641</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114522003634</pub-id>
<pub-id pub-id-type="pmid">36377535</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0036"><mixed-citation publication-type="journal" id="efs29470-cit-0036">
<string-name>
<surname>Sarapis</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Hoskin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>George</surname>, <given-names>E. S.</given-names>
</string-name>, <string-name>
<surname>Marx</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>, <given-names>H. L.</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Pipingas</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Willcox</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Prendergast</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Itsiopoulos</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Moschonis</surname>, <given-names>G.</given-names>
</string-name> (<year>2020</year>). <article-title>The effect of high polyphenol extra virgin olive oil on blood pressure and arterial stiffness in healthy Australian adults: A randomized, controlled, Cross&#x02010;over Study</article-title>. <source>Nutrients</source>, <volume>12</volume>, <fpage>2272</fpage>. <pub-id pub-id-type="doi">10.3390/nu12082272</pub-id>
<pub-id pub-id-type="pmid">32751219</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0037"><mixed-citation publication-type="journal" id="efs29470-cit-0037">
<string-name>
<surname>Schwingshackl</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Krause</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schmucker</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>R&#x000fc;cker</surname>, <given-names>G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Meerpohl</surname>, <given-names>J. J.</given-names>
</string-name> (<year>2019</year>). <article-title>Impact of different types of olive oil on cardiovascular risk factors: A systematic review and network meta&#x02010;analysis</article-title>. <source>Nutrition, Metabolism, and Cardiovascular Diseases</source>, <volume>29</volume>, <fpage>1030</fpage>&#x02013;<lpage>1039</lpage>. <pub-id pub-id-type="doi">10.1016/j.numecd.2019.07.001</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0038"><mixed-citation publication-type="journal" id="efs29470-cit-0038">
<string-name>
<surname>Singleton</surname>, <given-names>V. L.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Rossi</surname>, <given-names>J. A.</given-names>
</string-name> (<year>1965</year>). <article-title>Colorimetry of Total phenolics with phosphomolybdic&#x02010;Phosphotungstic acid reagents</article-title>. <source>American Journal of Enology and Viticulture</source>, <volume>16</volume>, <elocation-id>144</elocation-id>. <pub-id pub-id-type="doi">10.5344/ajev.1965.16.3.144</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0042"><mixed-citation publication-type="journal" id="efs29470-cit-0042">
<string-name>
<surname>Sun</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Ji</surname>, <given-names>B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Zhou</surname>, F.</string-name> (<year>2021</year>). <article-title>Bioactivity of Dietary Polyphenols: The Role in LDL&#x02010;C Lowering</article-title>. <source>Foods</source>, 10(11):2666. <pub-id pub-id-type="doi">10.3390/foods10112666</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0039"><mixed-citation publication-type="journal" id="efs29470-cit-0039">
<string-name>
<surname>Stoclet</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Chataigneau</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ndiaye</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Oak</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>El Bedoui</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chataigneau</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Schini&#x02010;Kerth</surname>, <given-names>V. B.</given-names>
</string-name> (<year>2004</year>). <article-title>Vascular protection by dietary polyphenols</article-title>. <source>European Journal of Pharmacology</source>, <volume>500</volume>, <fpage>299</fpage>&#x02013;<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2004.07.034</pub-id>
<pub-id pub-id-type="pmid">15464042</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0040"><mixed-citation publication-type="journal" id="efs29470-cit-0040">
<string-name>
<surname>Weinbrenner</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Fit&#x000f3;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de la Torre</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Saez</surname>, <given-names>G. T.</given-names>
</string-name>, <string-name>
<surname>Rijken</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Tormos</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Coolen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Albaladejo</surname>, <given-names>M. F.</given-names>
</string-name>, <string-name>
<surname>Abanades</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Schroder</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Marrugat</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Covas</surname>, <given-names>M. I.</given-names>
</string-name> (<year>2004</year>). <article-title>Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men</article-title>. <source>The Journal of Nutrition</source>, <volume>134</volume>, <fpage>2314</fpage>&#x02013;<lpage>2321</lpage>. <pub-id pub-id-type="doi">10.1093/jn/134.9.2314</pub-id>
<pub-id pub-id-type="pmid">15333722</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0041"><mixed-citation publication-type="journal" id="efs29470-cit-0041">
<string-name>
<surname>Yang</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Le</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name> (<year>2006</year>). <article-title>Effect of antioxidant capacity on blood lipid metabolism and lipoprotein lipase activity of rats fed a high&#x02010;fat diet</article-title>. <source>Nutrition</source>, <volume>22</volume>, <fpage>1185</fpage>&#x02013;<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2006.08.018</pub-id>
<pub-id pub-id-type="pmid">17095404</pub-id>
</mixed-citation></ref><ref id="efs29470-bib-0043"><mixed-citation publication-type="journal" id="efs29470-cit-0043">
<string-name>
<surname>Zupo</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Castellana</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Crupi</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Desantis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Rondanelli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Corbo</surname>, <given-names>F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Clodoveo</surname>, <given-names>M. L.</given-names>
</string-name> (<year>2023</year>). <article-title>Olive oil polyphenols improve HDL cholesterol and promote maintenance of lipid metabolism: A systematic review and meta&#x02010;analysis of randomized controlled trials</article-title>. <source>Metabolites</source>, <volume>13</volume>. <pub-id pub-id-type="doi">10.3390/metabo13121187</pub-id>
</mixed-citation></ref></ref-list><app-group><app id="efs29470-app-0001" content-type="APPENDIX"><label>APPENDIX A</label><title>Outcome of the public consultation</title><p>A total of six comments and nine attachments were submitted by five interested parties, four being from Spain and one with the country of origin not declared. The comments, along with attachments submitted, are published on the EFSA web page as received: <ext-link xlink:href="https://open.efsa.europa.eu/consultations/a0cTk00000CHrW2IAL?status=Closed" ext-link-type="uri">https://open.efsa.europa.eu/consultations/a0cTk00000CHrW2IAL?status=Closed</ext-link>
</p><p>Attachments submitted as part of a comment can be accessed via the Open EFSA web page. Comments made therein are addressed under the respective entry. The comments that have been submitted in relation to this public consultation are addressed below.<table-wrap position="anchor" id="jats-table-wrap-1"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Respondent</th><th align="left" valign="bottom" rowspan="1" colspan="1">Comment and reply</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Universidad de Cordoba (Spain)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 1</bold>: Letter of support from C&#x000e1;tedra de Gastronom&#x000ed;a Mediterr&#x000e1;nea</p>
<p>
<bold>Reply</bold>: EFSA acknowledges the comment and notes that no additional information/data that is relevant for the scientific substantiation of the claim has been submitted.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JOSE J. GAFORIO (Unknown country)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 2:</bold> Dear European Food Safety Authority Members, I am writing to express my strong support for the health claim application submitted by QvExtra! Internacional, regarding Virgin Olive oil. This application, made under Article 14 of Regulation (EC) No 1924/2006, focuses on disease risk reduction.</p>
<p>My support is based on the understanding that virgin olive oil naturally contains phenolic compounds, which contribute to reducing LDL&#x02010;cholesterol levels and arterial systolic blood pressure. Lowering LDL&#x02010;cholesterol and systolic blood pressure is directly linked to a decreased risk of coronary heart disease.</p>
<p>I believe that the evidence strongly supports the proposed health claim and I am confident that its approval would benefit public health.</p>
<p>Yours sincerely,</p>
<p>Jos&#x000e9; J Gaforio</p>
<p>
<bold>Reply</bold>: EFSA acknowledges the comment and notes that no additional information/data that is relevant for the scientific substantiation of the claim has been submitted.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Miguel &#x000c1;ngel Mart&#x000ed;nez&#x02010;Gonz&#x000e1;lez (Spain)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 3:</bold> Please find my letter attached</p>
<p>
<bold>Reply</bold>: EFSA acknowledges the comment and notes that no additional information/data that is relevant for the scientific substantiation of the claim has been submitted.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Instituto de la Grasa CSIC (Spain)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 4:</bold>
</p>
<p>To European Food Safety Authority (EFSA): With this letter, I would like to show my support in relation to the Public Consultation (PC&#x02010;1329) titled: Application for the authorisation of &#x02018;Virgin Olive Oils&#x02019; as a Health Claim (Art. 14).</p>
<p>As my CV indicates, I am a Senior Scientist at the Instituto de la Grasa del CSIC. The Institute was created in 1947 with the aim of contributing to the improvement and development of the industrial sectors related to oils and fats. Since its foundation, it has devoted special attention to the olive oil and table olive sectors, which are of great economic and social importance in Andalucia, making a decisive contribution to improving the scientific and technological level of both sectors through the development of olive oil processing technology, seed oil extraction and refining technology, conservation and packaging, oxidative alterations, biotechnology of table olive processing, preparation of analytical criteria and methods, bases for the elaboration of quality standards, etc.</p>
<p>Within the aforementioned centre, I lead a research group within the Department of Food and Health, having devoted my scientific career to the study of bioactive compounds in foods such as olive oil and vegetable by&#x02010;products and the evaluation of their effect on the immune system, mainly from the point of view of the prevention or reduction of disease risk factors through food as an alternative therapy to classic pharmacotherapy.</p>
<p>For all the scientific information I have in relation to nutrition and health and for my participation as a member of the scientific committee of the proposal, I reiterate my endorsement of the request for authorisation of &#x02018;Virgin olive oils&#x02019; as a health claim submitted by QvExtra International. Specifically, I would like to contribute three scientific publications of great importance that could be contributed to the dossier as additional information regarding the positive effect of the phenols of virgin and extra virgin olive oil in the reduction of blood pressure and LDLc with respect to other fats in short interventions and more than 8&#x02009;weeks, as well as the possible mechanisms of action:</p>
<p>Publications 1. Oleg Frumuzachi, Helena Kieserling, Sascha Rohn &#x00026; Andrei Mocan (2025): The impact of oleuropein, hydroxytyrosol, and tyrosol on cardiometabolic risk factors: a meta&#x02010;analysis of randomised controlled trials, Critical Reviews in Food Science and Nutrition, <ext-link xlink:href="https://doi.org/10.1080/10408398.2025.2453090" ext-link-type="uri">https://doi.org/10.1080/10408398.2025.2453090</ext-link> Copyright: OPEN ACCESS &#x000a9; 2025 The Author(s). Published with licence by Taylor &#x00026; Francis Group, LLC.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>This study information on the dietary effect of olive oil polyphenols on cardiovascular parameters, mechanism of action and effect in interventions longer than 8&#x02009;weeks: Mechanistically, oleuropein (OLE), hydroxytyrosol (HT), and tyrosol (TYR) modulate lipid metabolism by enhancing the activity of enzymes involved in lipid breakdown and by inhibiting enzymes involved in lipid synthesis. They upregulate lipoprotein lipase, which breaks down triacylglycerols, and inhibits HMG&#x02010;CoA reductase, a key enzyme in cholesterol synthesis (Markovi&#x00107; et&#x000a0;al. 2019). Thus, OLE, HT and TYR consistently improve lipid profiles in animal models by reducing TC, LDL&#x02010;C and TAG levels and increasing HDL&#x02010;C levels, with higher doses yielding more significant improvements. In some human trials, it was observed that HT in combination with red yeast rice extract and punicalagin reduce TC, LDL&#x02010;C and TAG, while increasing HDL&#x02010;C.</p>
<p>The meta&#x02010;analysis indicated that studies extending beyond 8&#x02009;weeks significantly reduced LDL&#x02010;C levels, suggesting that extended exposure to OLE, HT and TYR is necessary to achieve meaningful lipid&#x02010;lowering effects. This observation aligns with literature findings, where prolonged supplementation with olive leaf extract or regular consumption of olive oil results in reductions in LDL&#x02010;C, thereby enhancing cardiovascular health (Estruch et&#x000a0;al. 2018; Razmpoosh et&#x000a0;al. 2022).</p>
<p>Markovi&#x00107;, A. K., J. Tori&#x00107;, M. Barbari&#x00107;, and C. J. Brala. (2019). Hydroxytyrosol, tyrosol, and derivatives and their potential effects on human health. Molecules (Basel, Switzerland), 24, 2001. <ext-link xlink:href="https://doi.org/10.3390/MOLECULES24102001" ext-link-type="uri">https://doi.org/10.3390/MOLECULES24102001</ext-link>.</p>
<p>Estruch, R., E. Ros, J. Salas&#x02010;Salvad&#x000f3;, M.&#x02010;I. Covas, D. Corella, F. Ar&#x000f3;s, E. G&#x000f3;mez&#x02010;Gracia, V. Ruiz&#x02010;Guti&#x000e9;rrez, M. Fiol, and J. Lapetra. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra&#x02010;virgin olive oil or nuts. New England Journal of Medicine, 378(25):e34(1)&#x02013;e34(14). <ext-link xlink:href="https://doi.org/10.1056/NEJMoa1800389" ext-link-type="uri">https://doi.org/10.1056/NEJMoa1800389</ext-link>.</p>
<p>Razmpoosh, E., S. Abdollahi, M. Mousavirad, C. C. T. Clark, and S. Soltani. (2022). The effects of olive leaf extract on cardiovascular risk factors in the general adult population: A systematic review and meta&#x02010;analysis of randomized controlled trials. Diabetology &#x00026; Metabolic Syndrome, 14(1), 1&#x02013;15. <ext-link xlink:href="https://doi.org/10.1186/s13098-022-00920-y" ext-link-type="uri">https://doi.org/10.1186/s13098&#x02010;022&#x02010;00920&#x02010;y</ext-link>.</p>
<p>2. Zupo, R., Castellana, F., Crupi, P., Desantis, A., Rondanelli, M., Corbo, F., and Clodoveo, M. S. (2023): Olive Oil Polyphenols Improve HDL Cholesterol and Promote Maintenance of Lipid Metabolism: A Systematic Review and Meta&#x02010;Analysis of Randomized Controlled Trials. Metabolites, 13, 1187. <ext-link xlink:href="https://doi.org/10.3390/metabo13121187" ext-link-type="uri">https://doi.org/10.3390/metabo13121187</ext-link> Copyright: &#x000a9; 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>).</p>
<p>This meta&#x02010;analysis of 10 human randomized clinical trials (RCTs) adds new evidence based on the exposure to olive oil, and specifically its polyphenols, whereby it significantly improves circulating HDL&#x02010;C levels without affecting the TC levels, while also potentially reducing circulating LDL&#x02010;C levels following the consumption of high daily concentrations (268&#x02013;600 mg/kg). The healthy benefits of olive oil extend further than its lipid fraction, as its polyphenols showed potential in maintaining lipid metabolism. Labelling frameworks should highlight this health feature of extra virgin olive oil as the main constituent of the Mediterranean diet, whereby a higher polyphenol content occurs from mechanical extraction. Moreover, it is also advisable to declare the polyphenol content of this product in the market. Therefore, consumers will be made more aware of the quality and possible health effects of the products they are consuming since the implementation of nutrition labels offers the best means of information.</p>
<p>3. Liang, F., Young, Y., Koutsidis, G., and Gallegos, J. L. (2023). The effects of extra virgin olive oil or butter on cardiovascular biomarkers in European and Chinese males in the UK: A pilot randomised crossover trial. <italic toggle="yes">Nutrition and Health</italic>, 2023. <ext-link xlink:href="https://doi.org/10.1177/02601060231187516" ext-link-type="uri">https://doi.org/10.1177/02601060231187516</ext-link> Copyright: &#x000a9; The Author(s) 2023.</p>
<p>The findings of this pilot study suggest that consumption of extra virgin olive oil (EVOO) for 2&#x02009;weeks, instead of butter, is associated with significantly lower 24&#x02010;h SBP including day&#x02010;time SBP, night time DBP and night&#x02010;time MAP, as well as TC, LDL&#x02010;C, in healthy male volunteers. However, differences were observed between Caucasians and East Asian individuals in the absence of significant differences in lifestyle. Thus, further research on this area is warranted, and the study of other ethnic groups should be encouraged. In conclusion, consumption of EVOO, instead of butter, could improve cardiovascular health of individuals, however, it is currently acknowledged that evidence on the effect of EVOO on plasma lipids is still controversial and further research is required before drawing solid conclusions.</p>
<p>EVOO or butter were purchased from Tesco &#x02013; Tesco organic unsalted butter and Filippo Berio Organic EVOO. The nutritional composition of these is presented in Supplemental Table&#x000a0;10. However lack of data on the phenolic composition of EVOO and butter used in this study, which is undoubtedly a limitation to the study. In this regard it should be noted that all production processes are regularly subject to methodical verification by experts and accredited external certification boards to guarantee the quality of Filippo Berio products. A part from its own rigorous standards and tests designed to enhance the quality of its oils, SALOV is also certified by the ISO &#x02013; one of the leading quality control organisations as well as the British Retail Consortium (BRI) and the International Food Standard (IFS). Filippo Berio is also certified Kosher.</p>
<p>The high standards of SALOV are witnessed by the numerous certifications that concern not only the quality of products, but also of the plant and the processes, as well as the care and attention paid to the environment and the health and safety of workers.</p>
<p>Table&#x000a0;S10. Determination of fatty acids as the corresponding fatty acid methyl esters in olive oil and butter samples (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3). Only fatty acids with a % higher than 0.3% and/or identified are reported. (These data are included in the attached).</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fatty acid/ Olive oil (%)/Butter (%)</p>
<p>Butyric C4:0&#x02013;1.8 (&#x000b1;&#x02009;0.1)</p>
<p>Caproic C6:0&#x02013;0.3 ((&#x000b1;&#x02009;0.08)</p>
<p>Caprylic C8:0&#x02013;0.5 (&#x000b1;&#x02009;0.1)</p>
<p>Capric C10:0&#x02013;1.8 (&#x000b1;&#x02009;0.1)</p>
<p>Lauric C12:0&#x02013;2.9 (&#x000b1;0.03)</p>
<p>Myristic C14:0&#x02013;10.9 (&#x000b1;0.07)</p>
<p>Pentadecanoic C15:0&#x02013;1.2 (&#x000b1;0.02)</p>
<p>Palmitic C16:0 13.3 (&#x000b1;&#x02009;0.1) 31.0 (&#x000b1;0.12)</p>
<p>Palmitoleic C16:1n&#x02010;7 0.95 ((&#x000b1;&#x02009;0.05) &#x02013;</p>
<p>Heptadecanoic C17:0&#x02013;0.9 (&#x000b1;0.07)</p>
<p>Stearic C18:0 2.8 (&#x000b1;&#x02009;0.1) 14.5 (&#x000b1;0.12)</p>
<p>Oleic C18:1n&#x02010;9 72.6 (&#x000b1;&#x02009;0.7) 25.1 (&#x000b1;0.15)</p>
<p>Linoleic C18:2n&#x02010;6 6.8 (&#x000b1;&#x02009;0.2) 1.6 (&#x000b1;0.14)</p>
<p>Vaccenic C18:1n&#x02010;7 2.3 (&#x000b1;&#x02009;0.1) 0.9 (&#x000b1;0.01)</p>
<p>Linolenic C18:3n&#x02010;3 0.3 (&#x000b1;&#x02009;0.01) 0.6 (&#x000b1;0.06)</p>
<p>Saturated 16.1 64.8</p>
<p>Monounsaturated 79.4 26</p>
<p>Polyunsaturated 7.2 2.2</p>
<p>For all these reasons, as it is a commercial organic extra virgin olive oil, it is assumed a high phenol content (over 200 mg/kg) according to current legislation, so the positive effect of the oil could be due to the minority compounds (natural phenolic compounds from virgin olive oils) not present in butter.</p>
<p>
<bold>Reply</bold>: In relation to the publication by Frumuzachi et&#x000a0;al. (2025), the Panel notes that the studies included in the systematic review were conducted using foods enriched with polyphenols from various sources, pure compounds, or standardised supplements rather than polyphenols naturally occurring in olive oils, which is the food/constituent of the proposed claim under assessment. The Panel considers that these publications are not pertinent for the scientific substantiation of the claim.</p>
<p>The publication by Estruch et&#x000a0;al. (2018), already submitted by the applicant, reports on the PREDIMED study which investigated the effects of extra virgin olive oil with unknown polyphenol content administered as part of a Mediterranean diet intervention versus a low&#x02010;fat diet, without controlling for the co&#x02010;intervention, from which the Panel could not draw conclusions for the scientific substantiation of the claim (see Section&#x000a0;<xref rid="efs29470-sec-0019" ref-type="sec">3.3</xref> of the opinion).</p>
<p>In relation to the systematic review and meta&#x02010;analysis by Razmpoosh et&#x000a0;al. (2022), the Panel notes that the review investigated the effects of olive leaf extract supplementation on cardiovascular&#x02010;related variables. As the food/constituent under assessment is polyphenols naturally present in olive oil, the Panel considers that these publications are not pertinent for the scientific substantiation of the claim.</p>
<p>The narrative review by Markovi&#x00107; et&#x000a0;al. (2019) discusses a broad range of biological activities, as well as the metabolism and bioavailability of the major olive oil polyphenols which may influence lipid metabolism and systolic blood pressure. The Panel considers that the mechanisms by which olive oil polyphenols may reduce LDL&#x02010;c or blood pressure discussed in this review have already been proposed by the applicant.</p>
<p>In relation to the systematic review and meta&#x02010;analysis by Zupo et&#x000a0;al. (<xref rid="efs29470-bib-0043" ref-type="bibr">2023</xref>), the Panel notes that seven of the 10 RCTs included had already been submitted by the applicant and are evaluated in the opinion. With regard to the remaining three studies (Konstantinidou et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0021" ref-type="bibr">2010</xref>; Santangelo et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0034" ref-type="bibr">2016</xref>; Weinbrenner et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0040" ref-type="bibr">2004</xref>), which were recently evaluated in the context of an Article 13.5 health claim application on olive oil polyphenols and maintenance of normal HDL&#x02010;c cholesterol concentrations (EFSA NDA Panel,&#x000a0;<xref rid="efs29470-bib-0010" ref-type="bibr">2025</xref>), the Panel considered that no conclusions could be drawn from these studies or from the systematic review and meta&#x02010;analysis (Zupo et&#x000a0;al., <xref rid="efs29470-bib-0043" ref-type="bibr">2023</xref>) owing to several methodological limitations that remain applicable in the present assessment. Specifically, in Konstantinidou et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0021" ref-type="bibr">2010</xref>), the lack of reported absolute olive oil intake and the absence of a quantification of polyphenol consumption preclude any assessment of the independent effects of olive oil polyphenols on blood lipid concentrations. Similarly, in Santangelo et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0034" ref-type="bibr">2016</xref>), the sequential, non&#x02010;randomised design, the absence of a washout period, the high attrition rate and the uncorrected multiple comparisons undermine the reliability of the findings. The 4&#x02010;day duration of the study by Weinbrenner et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0040" ref-type="bibr">2004</xref>) does not allow for conclusions to be drawn on the sustained effect of olive oil polyphenols on blood lipid concentrations.</p>
<p>Finally, in the study by Liang et&#x000a0;al. (2023), the use of an inappropriate comparator (butter), which differs substantially in composition from extra virgin olive oil, and the lack of a quantification of polyphenol content in the olive oil, preclude any conclusions regarding the independent effects of olive oil polyphenols on LDL&#x02010;c or blood pressure.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Instituto de la Grasa CSIC (Spain)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 5:</bold> Publications to consider as additional information in the application:</p>
<p>1. Frumuzachi, O., Kieserling, H., Rohn, S., &#x00026; Mocan, A. (2025): The impact of oleuropein, hydroxytyrosol, and tyrosol on cardiometabolic risk factors: A meta&#x02010;analysis of randomized controlled trials. <italic toggle="yes">Critical Reviews in Food Science and Nutrition</italic>. <ext-link xlink:href="https://doi.org/10.1080/10408398.2025.2453090" ext-link-type="uri">https://doi.org/10.1080/10408398.2025.2453090</ext-link>
</p>
<p>2. Zupo, R., Castellana, F., Crupi, P., Desantis, A., Rondanelli, M., Corbo, F., and Clodoveo, M.L. (2023). Olive oil polyphenols improve HDL cholesterol and promote maintenance of lipid metabolism: a systematic review and meta&#x02010;analysis of randomized controlled trials. <italic toggle="yes">Metabolites</italic>, 13, 1187. <ext-link xlink:href="https://doi.org/10.3390/metabo13121187" ext-link-type="uri">https://doi.org/10.3390/metabo13121187</ext-link>
</p>
<p>3. Liang, F., Young, J., Koutsidis, G., and Gallegos, J. L. (2023). The effects of extra virgin olive oil or butter on cardiovascular biomarkers in European and Chinese males in the UK: A pilot randomised crossover trial. <italic toggle="yes">Nutrition and Health</italic>. <ext-link xlink:href="https://doi.org/10.1177/02601060231187516" ext-link-type="uri">https://doi.org/10.1177/02601060231187516</ext-link>
</p>
<p>
<bold>Reply:</bold> See reply to the comment above in relation to these three studies.</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eduard ESCRICH (Spain)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<bold>Comment 6:</bold> I attach a letter and CV to support declaration PC&#x02010;1329.</p>
<p>
<bold>Reply</bold>: EFSA acknowledges the comment and notes that no additional information/data that is relevant to the scientific substantiation of the claim has been submitted.</p>
</td></tr></tbody></table></table-wrap>
</p></app><app id="efs29470-app-0002" content-type="APPENDIX"><label>APPENDIX B</label><title>Evidence tables</title><table-wrap position="anchor" id="efs29470-tbl-0001" content-type="TABLE"><label>TABLE B.1</label><caption><p>Evidence table of human studies submitted for the scientific substantiation of the claimed effect.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Reference country</th><th align="left" valign="bottom" rowspan="1" colspan="1">Design subject characteristics <italic toggle="yes">N</italic>&#x02009;=&#x02009;number randomised <italic toggle="yes">n</italic>&#x02009;=&#x02009;number analysed</th><th align="left" valign="bottom" rowspan="1" colspan="1">Intervention</th><th align="left" valign="bottom" rowspan="1" colspan="1">Endpoint(s) assessed and methods</th><th align="left" valign="bottom" rowspan="1" colspan="1">Statistical analyses</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>)</p>
<p>Spain, Denmark, Germany, Italy, Finland</p>
<p>EUROLIVE Project</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled: Healthy males</p>
<p>Inclusion criteria: in good health and willingness to adhere to the protocol</p>
<p>Exclusion criteria: smoking, use of antioxidant supplements, aspirin or any drug with antioxidant properties, hyperlipidaemia, diabetes, intestinal disease</p>
<p>Age (y): 20&#x02013;60</p>
<p>Sex: males</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;200|<italic toggle="yes">n</italic>&#x02009;=&#x02009;183</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Duration: 3&#x02009;weeks</p>
<p>Olive Oil Daily Dose<xref rid="efs29470-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>:</p>
<p>25 mL (22.9 g)</p>
<p>Polyphenol content, mg/kg (daily dose)</p>
<p>G1(High): 366 (8.4)</p>
<p>G2(Med): 164 (3.8)</p>
<p>G3(Low): 2.7 (0.1)</p>
<p>Polyphenol measurement method: NR but in another publication it was reported to be HPLC&#x02010;DAD and MS/MS with 629 and 0 mg/kg for the high and low polyphenol olive oils, respectively (de la Torre&#x02010;Carbot et&#x000a0;al. <xref rid="efs29470-bib-0050" ref-type="bibr">2010</xref>).</p>
<p>Compliance: Participant adherence was good, as reflected in the changes in urinary tyrosol and hydroxytyrosol excretion after olive oil interventions</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fasting blood samples</p>
<p>HDL&#x02010;c: determined by enzymatic methods</p>
<p>LDL&#x02010;c: calculated by the Friedewald formula</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>ITT analysis</p>
<p>General linear model using post&#x02010;intervention values as dependent variables and including period, treatment, and centre as fixed effects; participant number as a random effect; and age and baseline values as covariates</p>
<p>A period&#x02010;by&#x02010;treatment interaction term was tested in general linear mixed models to check for carryover effects. Since this term was not significant, it was excluded from the final models.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>HDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold>
</p>
<p>G1: 0.045 (0.02, 0.06)</p>
<p>G2: 0.032 (0.005, 0.05)</p>
<p>G3: 0.025 (0.003, 0.05)</p>
<p>
<italic toggle="yes">P</italic>
<sub>trend</sub>&#x02009;=&#x02009;0.018</p>
<p>Mean post&#x02010;intervention (mmol/L)</p>
<p>G1: 1.30</p>
<p>G2: 1.27</p>
<p>G3: 1.27</p>
<p>Between&#x02010;group differences (mmol/L)</p>
<p>G1 versus G3: 0.029 (0.005 to 0.06)</p>
<p>G1 versus G2: 0.025 (0.001 to 0.05)</p>
<p>G2 versus G3: 0.006 (&#x02212;0.01 to 0.02)</p>
<p>
<underline underline-style="single">
<bold>LDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold>
</p>
<p>G1: &#x02212;0.010 (&#x02212;0.08, 0.06)</p>
<p>G2: &#x02212;0.019 (&#x02212;0.1, 0.05)</p>
<p>G3: 0.015 (&#x02212;0.06, 0.09)</p>
<p>
<italic toggle="yes">P</italic>
<sub>trend</sub>&#x02009;=&#x02009;0.74</p>
<p>Mean post&#x02010;intervention (mmol/L)</p>
<p>G1: 2.98</p>
<p>G2: 2.93</p>
<p>G3: 2.97</p>
<p>Between&#x02010;group differences (mmol/L)</p>
<p>G1 versus G3: 0.014 (&#x02212;0.07 to 0.12)</p>
<p>G1 versus G2: &#x02212;0.041 (&#x02212;0.09 to 0.07)</p>
<p>G2 versus G3: &#x02212;0.050 (&#x02212;0.13 to 0.05)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Mart&#x000ed;n&#x02010;Pel&#x000e1;ez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0024" ref-type="bibr">2017</xref>)</p>
<p>Spain, Germany, Finland</p>
<p>Subsample of the EUROLIVE Project</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled and inclusion/exclusion criteria same as above for Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>)</p>
<p>Age (y): 36&#x02009;&#x000b1;&#x02009;11.1</p>
<p>Sex: males</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;200|<italic toggle="yes">n</italic>&#x02009;=&#x02009;18</p>
<p>Random subsample of the EUROLIVE</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Same as above for Covas et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0004" ref-type="bibr">2006</xref>)</p>
<p>G2 (medium polyphenol content oil arm) not reported</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">BP (secondary outcome): measured twice, with a mercury sphygmomanometer after at least a 10&#x02010;min rest in the seated position</td><td align="left" valign="top" rowspan="1" colspan="1">Adjusted general linear mixed models with a period&#x02010;by&#x02010;treatment interaction term were used for inter&#x02010;intervention comparisons</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>Baseline measurements</bold>
</underline>
</p>
<p>
<bold>Mean&#x02009;&#x000b1;&#x02009;SD (mmHg)</bold>
</p>
<p>SBP: 127 14</p>
<p>DBP: 78 9</p>
<p>
<underline underline-style="single">
<bold>Changes in BP after oil intervention</bold>
</underline>
</p>
<p>
<bold>Mean&#x02009;&#x000b1;&#x02009;SE (mmHg)</bold>
</p>
<p>
<underline underline-style="single">SBP</underline>
</p>
<p>G1: &#x02212;4.222&#x02009;&#x000b1;&#x02009;1.813 <italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.05</p>
<p>G3: 0.444&#x02009;&#x000b1;&#x02009;1.813</p>
<p>
<italic toggle="yes">P</italic> for inter&#x02010;olive oil intervention comparison&#x02009;=&#x02009;0.06</p>
<p>
<underline underline-style="single">DBP</underline>
</p>
<p>G1: &#x02212;2.112&#x02009;&#x000b1;&#x02009;1.340</p>
<p>G3: 2.944&#x02009;&#x000b1;&#x02009;1.340 <italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.05</p>
<p>
<italic toggle="yes">P</italic> for inter&#x02010;olive oil intervention comparison&#x02009;=&#x02009;0.007</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Sarapis et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0036" ref-type="bibr">2020</xref>)</p>
<p>Sarapis et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0035" ref-type="bibr">2023</xref>)</p>
<p>Australia</p>
<p>OLIVAUS</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Double&#x02010;blind, cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled: Healthy adults</p>
<p>Inclusion criteria: Age: 18&#x02013;75&#x02009;years, BMI between 18.5 and 40 kg/m<sup>2</sup>
</p>
<p>Exclusion criteria: non&#x02010;English speakers, pregnant/lactating women, adverse reactions to olive oil, habitual olive oil consumption (&#x02265;&#x02009;1 tbsp/day), special diets (vegetarian, coeliac, weight loss), diagnosed conditions (hyperlipidaemia, diabetes, hypertension, inflammatory/intestinal diseases, food intolerances, blood coagulation disorders, cognitive/mood disorders, other impairing conditions), prescribed medications (e.g. warfarin, anti&#x02010;coagulants, statins), inability to stop nutrient supplements (except iron, calcium, vitamin D), unstable body weight (&#x0003e;&#x02009;5&#x02009;kg fluctuation in 3 months), special medical diets (e.g. gluten&#x02010;free), current smoker</p>
<p>Age (y): 39 (14) (Range: 20&#x02013;70)</p>
<p>Sex: 66% females</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;50|<italic toggle="yes">n</italic>&#x02009;=&#x02009;43</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Duration: 3&#x02009;weeks</p>
<p>Olive Oil Daily Dose<xref rid="efs29470-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>: 60 mL (54.96 g)</p>
<p>Polyphenol content, mg/kg (daily dose)</p>
<p>G1(High): 320 (17.6)</p>
<p>G2(Low): 86 (4.7)</p>
<p>Polyphenol measurement method: HPLC</p>
<p>Compliance:</p>
<p>G1: 90%</p>
<p>G2: 92%</p>
<p>Based on measuring the volume of unconsumed olive oil returned at the end of each intervention period.</p>
<p>Participants were also asked to record daily volume of OO consumed over each 3&#x02010;week intervention period using a log sheet</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>HDL&#x02010;c (secondary outcome): standard enzyme assays</p>
<p>LDL&#x02010;c (secondary outcome): standard enzyme assays</p>
<p>Peripheral and central BP (secondary outcome): using applanation tonometry with a SphygmoCor XCEL device (mean of the last two out of three measurements) following a 5&#x02010;min rest in supine position.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>ITT analysis</p>
<p>Repeated&#x02010;measures ANOVA to examine treatment &#x000d7; time interaction effects</p>
<p>(differences in the changes from baseline to follow&#x02010;up between</p>
<p>the two intervention arms) &#x02010; Adjusted for sex and age</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>HDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold> (time effect)</p>
<p>G1: 0.10 (0.02, 0.19), <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>G2: 0.13 (0.04, 0.22), <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>
<italic toggle="yes">P</italic>
<sub>treatment x time</sub>&#x02009;=&#x02009;0.65</p>
<p>
<underline underline-style="single">
<bold>LDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold> (time effect)</p>
<p>G1: 0.14 (0.001, 0.28) <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>G2: 0.03 (&#x02212;0.11, 0.16)</p>
<p>
<italic toggle="yes">P</italic>
<sub>treatment x time</sub>&#x02009;=&#x02009;0.256</p>
<p>
<underline underline-style="single">Peripheral (brachial)</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold>
</p>
<p>
<underline underline-style="single">
<bold>SBP, mmHg</bold>
</underline>
</p>
<p>G1: &#x02212;2.5 (&#x02212;4.7, &#x02212;0.3), <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>G2: NR</p>
<p>
<italic toggle="yes">P</italic>
<sub>treatment x time</sub>&#x02009;=&#x02009;0.181</p>
<p>
<underline underline-style="single">Central (aortic</underline>)</p>
<p>G1: &#x02212;2.7 (&#x02212;4.7, &#x02212;0.6), <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>G2: NR</p>
<p>P<sub>treatment x time</sub>&#x02009;=&#x02009;0.208</p>
<p>No significant within&#x02010;group changes or between&#x02010;group differences were observed in peripheral and central DBP (data reported in graphical form only).</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Sanchez&#x02010;Rodriguez et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0033" ref-type="bibr">2018</xref>)</p>
<p>Spain</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Double&#x02010;blind, cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled: General population</p>
<p>Inclusion criteria: being in good health on the basis of a physical examination and basic biochemical and haematological analyses, and willingness to provide written informed consent.</p>
<p>Exclusion criteria: smoking, intake of antioxidant supplements, aspirin or any other drug with established antioxidant properties, hyperlipidaemia, obesity, diabetes, hypertension, coeliac or other intestinal disease, any condition limiting mobility, life&#x02010;threatening diseases or any other disease or condition that would impair compliance.</p>
<p>Age (y): 20&#x02013;50</p>
<p>Sex: 49% females</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;58|<italic toggle="yes">n</italic>&#x02009;=&#x02009;51</p>
<p>HDL&#x02010;c and LDL&#x02010;c could only be measured for 46 subjects</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Duration: 3&#x02009;weeks</p>
<p>Olive Oil Daily Dose<xref rid="efs29470-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>:</p>
<p>30 mL (27.48 g)</p>
<p>Polyphenol content, mg/kg (daily dose)</p>
<p>G1: 490 (13.5)</p>
<p>G2: 487 (13.2)</p>
<p>G3: 124 (3.4)</p>
<p>
<italic toggle="yes">G2 same as G1 in phenolic compounds but also enriched with triterpenes (389 ppm) from olive exocarp &#x02013; arm not pertinent to the claim</italic>
</p>
<p>Polyphenol measurement method: NR</p>
<p>Compliance: adherence to intervention measured using 24&#x02010;h urine from 12 random subjects by liquid chromatography coupled to a mass spectrometer</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fasting blood samples</p>
<p>HDL&#x02010;c(primary outcome): measured as soluble HDL&#x02010;c as determined using an accelerator selective detergent method</p>
<p>LDL&#x02010;c (primary outcome): calculated using the Friedewald formula</p>
<p>BP (secondary outcome): measured with a mercury sphygmomanometer after a minimum of 10 min resting in the seated position; the average of two measurements was recorded</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>ITT analysis</p>
<p>Linear mixed model was used to compare variables pre&#x02010;, and post&#x02010;intervention (i.e. intra&#x02010;treatment effect) as well as to compare between groups after the 3&#x02010;week intervention (i.e. inter&#x02010;treatment effect), adjusting for age, gender, pre&#x02010;intervention values and period as fixed effects and for subjects and hospital as random effects.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>HDL&#x02010;c (mg/dL)</bold>
</underline>
</p>
<p>Adjusted means &#x000b1; SEMs</p>
<p>Pre&#x02010;intervention</p>
<p>G1: 57&#x02009;&#x000b1;&#x02009;2</p>
<p>G3: 58&#x02009;&#x000b1;&#x02009;2</p>
<p>Post&#x02010;intervention:</p>
<p>G1: 60&#x02009;&#x000b1;&#x02009;2</p>
<p>G3: 59&#x02009;&#x000b1;&#x02009;2</p>
<p>NSD between&#x02010;groups (p not shown)</p>
<p>
<underline underline-style="single">
<bold>LDL&#x02010;c (mg/dL)</bold>
</underline>
</p>
<p>Pre&#x02010;intervention</p>
<p>G1: 104&#x02009;&#x000b1;&#x02009;4</p>
<p>G3: 105&#x02009;&#x000b1;&#x02009;4</p>
<p>Post&#x02010;intervention:</p>
<p>G1: 106&#x02009;&#x000b1;&#x02009;4</p>
<p>G3: 108&#x02009;&#x000b1;&#x02009;4</p>
<p>
<underline underline-style="single">
<bold>SBP (mmHg)</bold>
</underline>
</p>
<p>Pre&#x02010;intervention</p>
<p>G1: 119&#x02009;&#x000b1;&#x02009;3</p>
<p>G3: 117&#x02009;&#x000b1;&#x02009;3</p>
<p>Post&#x02010;intervention:</p>
<p>G1: 116&#x02009;&#x000b1;&#x02009;3</p>
<p>G3: 115&#x02009;&#x000b1;&#x02009;3</p>
<p>
<underline underline-style="single">
<bold>DBP (mmHg)</bold>
</underline>
</p>
<p>Pre&#x02010;intervention</p>
<p>G1: 75&#x02009;&#x000b1;&#x02009;2</p>
<p>G3: 72&#x02009;&#x000b1;&#x02009;2</p>
<p>Post&#x02010;intervention:</p>
<p>G1: 73&#x02009;&#x000b1;&#x02009;2</p>
<p>G3: 72&#x02009;&#x000b1;&#x02009;2</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fern&#x000e1;ndez&#x02010;Castillejo et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0014" ref-type="bibr">2016</xref>)</p>
<p>Spain</p>
<p>VOHF Study</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Double&#x02010;blind, cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled: Hypercholesterolemic individuals</p>
<p>Inclusion criteria: normal blood pressure, hypercholesterolemic (TC &#x0003e;&#x02009;200 mg/dL)</p>
<p>Exclusion criteria: smoking, LDL&#x02010;C&#x02009;&#x02265;&#x02009;190 mg/dL, TG &#x02265;&#x02009;350 mg/dL, fasting blood glucose &#x0003e;&#x02009;126 mg/dL, plasma creatinine levels &#x0003e;&#x02009;1.4 mg/dL for women and&#x02009;&#x0003e;&#x02009;1.5 mg/dL for men, BMI&#x02009;&#x0003e;&#x02009;35, smokers (&#x0003e;&#x02009;1 cigarette/day), athletes with physical activity (&#x0003e;&#x02009;3000 METS.min/day), hypertension, multiple allergies, intestinal diseases, chronic diseases (i.e. diabetes, cardiovascular, etc.) or other conditions that would impair the adherence to the study</p>
<p>Age (y): 23&#x02013;91</p>
<p>Sex: 42% females</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;33|<italic toggle="yes">n</italic>&#x02009;=&#x02009;33</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Duration: 3&#x02009;weeks</p>
<p>Olive Oil Daily Dose<xref rid="efs29470-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>:</p>
<p>25 mL (22.9&#x02009;g)</p>
<p>Polyphenol content, mg/kg (daily dose)</p>
<p>G1: 80 (1.8)</p>
<p>G2: 500 (11.5)</p>
<p>G3: 500 (11.5)</p>
<p>Both G2 and G3 are enriched VOO with its own phenolic compounds (PC). G3 is enriched with 250&#x02009;ppm of its own PC and 250&#x02009;ppm thyme PC</p>
<p>Polyphenol measurement method: NR in the paper, but reported to be Folin&#x02013;Ciocalteu for quantifying phenolic content and HPLC/MS/MS for phenolic profile analysis in another publication (Farr&#x000e0;s et&#x000a0;al.,&#x000a0;<xref rid="efs29470-bib-0012" ref-type="bibr">2015</xref>)</p>
<p>Compliance: considered &#x02018;good&#x02019; as reflected in the changes in urinary hydroxytyrosol sulfate and thymol sulfate excretion after olive oil interventions; measured using 24&#x02010;h urinary hydroxytyrosol&#x02010;sulfate (HPLC&#x02010;ESI&#x02010;MS/MS)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fasting blood samples</p>
<p>HDL&#x02010;c (secondary outcome): measured by an accelerator selective detergent method</p>
<p>LDL&#x02010;c (secondary outcome): calculated using the Friedewald formula</p>
<p>Peripheral BP (secondary outcome): measured with a mercury sphygmomanometer after at least a 10&#x02010;min rest in the seated position</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">ANCOVA was used to compare the changes in HDL, LDL and SBP among the different intervention groups while adjusting for covariates such as age, gender, sequence of olive oil administration, LDL&#x02010;C and baseline values.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>HDL&#x02010;c (mg/dL)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold>
</p>
<p>G1: 0.14 (&#x02212;2.4, 2.7)</p>
<p>G2: &#x02212;0.73 (&#x02212;3.5, 2.1)</p>
<p>
<italic toggle="yes">P</italic>
<sub>trend</sub>&#x02009;=&#x02009;ns</p>
<p>Mean post&#x02010;intervention (mg/dL)</p>
<p>G1: 52</p>
<p>G2: 53</p>
<p>Between&#x02010;group differences (mg/dL)</p>
<p>G2 versus G1: &#x02212;0.91 (&#x02212;4.8, 3.0)</p>
<p>NSD between groups</p>
<p>
<underline underline-style="single">
<bold>LDL&#x02010;c (mg/dL)</bold>
</underline>
</p>
<p>
<bold>Mean &#x00394; (95% CI)</bold>
</p>
<p>G1: 1.0 (&#x02212;3.2, 5.2)</p>
<p>G2: &#x02212;13 (&#x02212;17, &#x02212;9.4)</p>
<p>
<italic toggle="yes">P</italic>
<sub>trend</sub>&#x02009;&#x0003c;&#x02009;0.001 (quadratic trend)</p>
<p>Mean post&#x02010;intervention (mg/dL)</p>
<p>G1: 139</p>
<p>G2: 140</p>
<p>Between&#x02010;group differences (mg/dL)</p>
<p>G2 versus G1: &#x02212;14 (&#x02212;20, &#x02212;8.6) <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</p>
<p>
<underline underline-style="single">
<bold>SBP (mmHg)</bold>
</underline>
</p>
<p>No changes observed in blood pressure associated with the interventions (data not shown)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Marrugat et&#x000a0;al.&#x000a0;(<xref rid="efs29470-bib-0023" ref-type="bibr">2004</xref>)</p>
<p>Spain</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Double&#x02010;blind, cross&#x02010;over RCT, with 2&#x02010;week washout</p>
<p>Population sampled: Healthy non&#x02010;smoking males</p>
<p>Inclusion criteria: non&#x02010;smoking volunteers</p>
<p>Exclusion criteria: intake of antioxidant supplements, aspirin or any other drug with established antioxidant properties, obesity, dyslipidaemia, diabetes, coeliac or other intestinal disease, any condition limiting mobility, life&#x02010;threatening diseases or any other disease or condition that would impair compliance</p>
<p>Age (y): 20&#x02013;70</p>
<p>Sex: males</p>
<p>N&#x02009;=&#x02009;33|<italic toggle="yes">n</italic>&#x02009;=&#x02009;30</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Duration: 3&#x02009;weeks</p>
<p>Olive Oil Daily Dose<xref rid="efs29470-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>:</p>
<p>25 mL (22.9&#x02009;g)</p>
<p>Polyphenol content, mg/kg (daily dose)</p>
<p>G1: 0</p>
<p>G2: 68 (1.6)</p>
<p>G3: 150 (3.4)</p>
<p>Polyphenol measurement method: Folin&#x02013;Ciocalteu method and by HPLC</p>
<p>Compliance: Reported as excellent as reflected in the increase in urine T and HT concentrations after olive oil intervention periods</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Fasting blood samples</p>
<p>HDL&#x02010;c(secondary outcome): standard enzyme assays</p>
<p>LDL&#x02010;c(secondary outcome): calculated using the Friedewald formula</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>ITT analysis</p>
<p>General linear model for repeated measurements with multiple paired comparisons corrected by Tukey's method to assess differences among groups</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<underline underline-style="single">
<bold>HDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean&#x02009;&#x000b1;&#x02009;SD</bold>
</p>
<p>Baseline</p>
<p>G1: 1.58&#x02009;&#x000b1;&#x02009;0.34</p>
<p>G2: 1.57&#x02009;&#x000b1;&#x02009;0.34</p>
<p>G3: 1.57&#x02009;&#x000b1;&#x02009;0.29</p>
<p>Post&#x02010;intervention</p>
<p>G1: 1.62&#x02009;&#x000b1;&#x02009;0.34, <italic toggle="yes">p</italic>&#x02009;=&#x02009;ns</p>
<p>G2: 1.56&#x02009;&#x000b1;&#x02009;0.31, <italic toggle="yes">p</italic>&#x02009;=&#x02009;ns</p>
<p>G3: 1.65&#x02009;&#x000b1;&#x02009;0.32, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.029</p>
<p>
<underline underline-style="single">
<bold>LDL&#x02010;c (mmol/L)</bold>
</underline>
</p>
<p>
<bold>Mean (95% CI)</bold>
</p>
<p>Baseline</p>
<p>G1: 3.4&#x02009;&#x000b1;&#x02009;0.8</p>
<p>G2: 3.6&#x02009;&#x000b1;&#x02009;0.8</p>
<p>G3: 3.5&#x02009;&#x000b1;&#x02009;0.9</p>
<p>Post&#x02010;intervention</p>
<p>G1: 3.6&#x02009;&#x000b1;&#x02009;0.9, p&#x02009;=&#x02009;ns</p>
<p>G2: 3.4&#x02009;&#x000b1;&#x02009;0.8, p&#x02009;=&#x02009;ns</p>
<p>G3: 3.4&#x02009;&#x000b1;&#x02009;0.7, p&#x02009;=&#x02009;ns</p>
</td></tr></tbody></table><table-wrap-foot id="efs29470-ntgp-0002"><fn id="efs29470-note-0007"><p>
<italic toggle="yes">Note</italic>: Data presented as means (SD) unless otherwise stated.</p></fn><fn id="efs29470-note-0008"><p>Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of variance; BMI, body mass index; EUROLIVE, Effect of Olive Oil Consumption on Oxidative Damage in European Populations; HDL&#x02010;c, high&#x02010;density lipoprotein cholesterol; HPLC, high&#x02010;performance liquid chromatography; HPLC/MS/MS, high&#x02010;performance liquid chromatography tandem mass spectrometry; HPLC&#x02010;ESI&#x02010;MS/MS, high&#x02010;performance liquid chromatography&#x02010;electrospray tandem mass spectrometry; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; ITT, intention to treat; NSD, no significant difference; VOHF, Virgin Olive Oil and HDL Functionality.</p></fn><fn id="efs29470-note-0009"><label>
<sup>a</sup>
</label><p>Daily dose of olive oil in weight (grams) was calculated assuming an olive oil density of 0.916.</p></fn></table-wrap-foot></table-wrap></app></app-group></back></article>